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ABSTRACT 
Multi-drug resistance (MDR) has become a serious clinical problem for both cancer and 
infectious disease treatment.  One of the leading causes of MDR is the drug efflux mediated by 
the ATP-binding cassette (ABC) super-family of proteins which are found among diverse groups 
of organisms.  In our laboratory, we are interested in studying an ABC transporter DrrAB from 
Streptomyces peucetius. It confers resistance to two anticancer antibiotics doxorubicin and 
daunorubicin by its drug efflux function.  Insights into the function of the DrrAB complex are 
expected to facilitate a better understanding of mechanisms of MDR.  
The normal function of the DrrAB complex depends on the cis expression of both subu-
nits, DrrA and DrrB.  DrrA forms the nucleotide binding domain (NBD) and provides energy for 
drug translocation, while the DrrB protein functions as the transmembrane domain (TMD) and 
forms the substrate translocation pathway.  Studies on the detailed mechanisms of communica-
tion between DrrA and DrrB are critical for understanding the coupling of energy usage and sub-
strate translocation.  The present studies revealed the existence of two novel and functionally 
important modules in the C-terminal domain of DrrA that might be essential for conformational 
interplay between DrrA and DrrB during the catalytic cycle.  One module present at the extreme 
C terminus of DrrA consists of two separate motifs, DEF and CREEM.  CREEM motif together 
with its upstream region up to residue S319, interacts with the N-terminal cytoplasmic tail region 
of DrrB and forms an DrrA-DrrB interface, while the DEF motif regulates this interaction.  The 
second novel module GATE is present 104 amino acids upstream of DEF.  Based on our bio-
chemical and structural analyses, we propose that GATE functions as a transducer of conforma-
tional changes (resulting from ATP binding) from DrrA to DrrB.  Specifically, residue G215 pre-
sent in the Gly-loop, through its close contacts with residues in the Walker A motif in the NBD, 
senses the conformational changes resulting from ATP binding to Walker A.  Residue K227 in 
the GATE domain is then able to transduce those changes to the N terminus of DrrB via its inter-
action with S319 present in the extreme C terminus of DrrA.    
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INTRODUCTION  
MDR and ABC transporters 
Multi-drug resistance (MDR) has become a serious clinical problem for both cancer and 
infectious disease treatment in the last few decades.  It results in resistance to a broad variety of 
structurally and functionally unrelated drugs and antibiotics [1].  Bacterial cells employ multiple 
mechanisms to evade antibiotics, which include enzymatic modification of the drug, mutagenesis 
of drug targets, altered membrane permeability, and enhanced efflux pump expression [2].  Of 
these, drug efflux by dedicated membrane transporters is the most commonly seen mechanism 
for multi-drug resistance.  Most drug efflux proteins can be classified into five distinct protein 
families: the resistance-nodulation-cell division (RND), major facilitator (MF), staphylococcal 
small multidrug resistance (SMR), multidrug and toxic compound extrusion (MATE), and ATP-
binding cassette (ABC) families.  The first four families are driven by proton (and sodium) mo-
tive force, whereas ATP hydrolysis drives drug efflux in ABC transporters [2]. 
The ABC super-family of proteins is found among diverse groups of organisms.  They 
play pivotal roles in multiple biological processes including the import of different nutrients and 
export of various molecules.  Nevertheless, there are some ABC members that are involved in 
translation elongation and DNA repair [3]. One of the most extensively studied MDR-associated 
ABC transporter is the P-glycoprotein (ABC sub-family B member 1, ABCB1 or MDR1) found 
in human cancer cells.  MDR1 confers resistance to multiple drugs including doxorubicin, 
daunorubicin, colchicine, vincristine, vinblastine, rhodamine 123 and hoechst, etc [1].  The pro-
karyotic analogs of MDR1 include LmrA from Lactococcus lactis, the lipid flippase MsbA from 
Escherichia coli (E. coli) and Sav1866 from Staphylococcus aureus.  Recent knowledge about 
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the structure and function of these transporters has provided profound insights into the mecha-
nisms of ATP-dependent drug efflux [4-7]. 
The structure and mechanism of ABC transporters 
The basic structure of an ABC transporter consists of two transmembrane domains 
(TMDs) and two cytoplasmic nucleotide-binding domains (NBDs) [8].  The two TMDs together 
form the substrate translocation pathway, while the two NBDs form a head-to-tail interface 
which binds and hydrolyzes ATP to provide energy for substrate influx or efflux [8].  ABC 
transporters in eukaryotic cells commonly occur as a single large protein that contains all four 
domains.  In prokaryotes, however, most ABC transporters contain the TMD and the NBD on 
separate subunit. These subunits form a tetramer structure that is very similar to the eukaryotic 
ABC transporters [1].    
The NBD of an ABC protein contains all the characteristic motifs essential for ATP-
binding and hydrolysis, which include Walker A, Q-loop, ABC signature, Walker B, D-loop and 
the Switch.  The tertiary structure of the NBD exhibits two domains: the larger domain referred 
to as the ‘RecA-like’ domain that contains the Walker A (GxxGxGKS/T, where x represents any 
amino acid) and Walker B (ффффD, where ф stands for a hydrophobic residue) motifs, and the 
smaller domain termed ‘helical domain’ which consists of three to four helices and the ABC sig-
nature (LSGGQ) motif [3].  The helical domain is sometimes also called the structurally diverse 
region (SDR), which may be involved in selectivity of particular substrates and the correspond-
ing communication between the NBD and TMD [9].  A motif called the Q-loop connects the Re-
cA-like domain and the helical domain.  In comparison to NBDs, TMDs from different ABC 
transporters share less similarity in their amino acid sequences.  Typically, each TMD contains 
3 
 
six to ten transmembrane α-helices, and a complete substrate translocation pathway requires the 
dimerization of TMDs.  
One open question about ABC transporter function concerns the mechanism underlying 
the power stroke of substrate translocation.  A widely accepted model known as the ‘ATP switch 
model’ for the transport cycle of an ABC exporter is shown in Fig. A [10].  Prior to the binding 
of the substrate to the inner leaflet of the membrane, the NBD dimer is in an open or resting state 
and TMDs are in the inward-facing conformation.  The translocation process is initiated by the 
binding of substrate to its binding site in TMDs (cyan and red), which increases the affinity of 
NBDs (blue and orange) for ATP.  Two molecules of ATP then bind to the ATP-binding pockets 
in a cooperative manner, which consequently induces the closed form of the NBD dimer.  The 
resulting conformational changes promote the transfer of TMDs from inward-facing to outward-
facing conformation followed by extrusion of the substrate.  In the third step, ATP is hydrolyzed 
followed by the sequential release of phosphate and ADP.  Consequently, the transporter is re-
stored to its resting state.  A large body of literature supports this model [8, 10, 11], however the 
detailed mechanisms involving the signaling between the NBD and the TMD as well as the cou-
pling of energy usage and substrate translocation still remain elusive.  It is generally accepted 
that conformational changes generated by ATP binding and/or hydrolysis are transmitted from 
the NBD to TMD through domain-domain interactions at the shared interface.  One of the earli-
est studies that investigated such interactions was carried out on the maltose transport system, 
MalFGK2.  Genetic studies showed that several functionally drastic mutants in a hydrophilic cy-
toplasmic loop in both TMDs, MalF and MalG, could be suppressed by mutations in the helical 
domain of MalK (the NBD component of the transporter), implying the importance of associa-
tion between these two domains [12].  A conserved sequence called the EAA motif was identi-
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fied in the above hydrophilic cytoplasmic loop in MalF and MalG, which was subsequently 
found to be present among several binding protein-dependent ABC importers [12].  A similar, 
though not identical, motif termed the EAA-like motif is present in ABC exporters [13], as de-
scribed later.  The focus of the present study is an ABC drug transporter DrrAB.  This study re-
ports identification of novel motifs in the ABC component DrrA and illustrates their role in in-
teraction with the N terminus of DrrB (which contains the EAA-like motif) and their possible 
role in energy transduction between DrrA and DrrB. 
 
 
 
 
 
Physiology (Bethesda), 2007. 22: p. 122-30. 
 
Fig. A  The ATP switch model of ABC exporters.  Step I, substrate binding to the pocket formed 
by the TMDs induces conformational changes in the NBDs, resulting in their increased affinity 
for ATP.  Step II, two molecules of ATP bind to the NBDs interface and induce the closed NBD 
dimer.  As a consequence, the resulting conformational changes trigger the TMDs to transfer 
from inward-facing to outward-facing conformation and the substrate is extruded.  Step III, ATP 
hydrolysis promotes further conformational changes in the TMDs.  Finally, the release of phos-
phate and then ADP restores the transporter to the resting state. 
 
The DrrAB system  
Streptomyces peucetius, a gram-positive bacterium, produces two anti-cancer chemother-
apeutic agents, doxorubicin and daunorubicin, and is self-resistant to these drugs.  The self-
resistance is conferred by an ABC efflux pump consisting of two proteins: the doxorubicin re-
sistance protein A (DrrA) and B (DrrB).  They are encoded by two open reading frames, drrA 
and drrB, within a gene cluster termed DNR/DXR [14].  After sub-cloning these two genes in an 
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E. coli expression vector, DrrA and DrrB could be expressed to form a functional transporter, 
which  was shown to facilitate doxorubicin efflux and confer doxorubicin resistance [15].   
DrrA is a 36-kDa protein consisting of 330 amino acid residues.  It is a  hydrophilic pe-
ripheral  membrane protein, which was shown to bind ATP or GTP in a Mg2+-dependent manner 
[15].  Sequence alignment of DrrA and NBDs from other ABC transporters suggested that DrrA 
possesses all the conserved motifs required for ATP catalysis in its N-terminal region (1-198 res-
idues) [16].  In a recent research work conducted in our lab, fluorescence resonance energy trans-
fer (FRET) studies confirmed the head-to-tail conformation of the DrrA dimer [16].  DrrB con-
tains 283 residues with predicted molecular weight of 30.6 kDa.  It is highly hydrophobic and is 
localized in the membrane [15].  Gene fusion studies showed that DrrB contains eight trans-
membrane helices with both the N and the C termini localized to the cytoplasm [17].  The com-
plete DrrAB transporter is proposed to be a tetramer consisting of two DrrA and two DrrB subu-
nits [18].   
Interactions between DrrA and DrrB are essential for assembly and function 
Previous studies have shown that DrrA plays an important role in stability of DrrB and 
that it may function  as a chaperone molecule [18].  When expressed alone in E. coli cells, DrrB 
is improperly assembled and is degraded [18].  When co-expressed with drrA either in cis or 
trans, the normal expression level of DrrB in the membrane is restored  [18].  Interestingly, DrrA 
fails to bind ATP in the absence of DrrB, indicating that DrrB is necessary for DrrA to acquire 
active conformation [18].  These data strongly suggest that DrrA and DrrB depend on each other 
for normal stability and function.  The finding that DrrA and DrrB proteins confer doxorubicin 
resistance only when the two proteins are expressed in cis in a translationally coupled manner 
further supports the notion that DrrA and DrrB proteins may be required to co-fold in order to 
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form a functional efflux pump [19].  These observations raise the questions: are there specific 
domains present in these two proteins that mediate the association between them and thus the 
proper assembly of the complex? Are these domains also involved in signal transduction be-
tween the two proteins during the drug translocation process?   
Important insights were obtained by using chemical cross-linking approaches.  Utilizing a 
heterobifunctional cysteine to amine cross linker GMBS, it was revealed that a cysteine substitu-
tion mutant S23C in the N-terminal cytoplasmic tail of DrrB (residue 1-53) interacts with a re-
gion in DrrA.  An conserved motif called the EAA-like motif (containing the consensus se-
quence GE-1..A3R/K..G7) was subsequently identified in this region of DrrB based on its se-
quence similarity to the conventional EAA motif found in ABC importers [16].  Such a motif has 
also been recently identified in TMDs from other ABC exporters [16].  In an attempt to explore 
the regions in DrrA that interact with S23C in the N-terminus of DrrB, a cysteine scan of the 
NBD (residue 1-198) of DrrA was carried out.  Disulfide cross-linking studies showed that S23C 
interacts with Y89C introduced in the Q-loop of DrrA.  These studies, therefore, defined an in-
teraction interface between DrrA and the N-terminus of DrrB.  Another important interaction in-
terface is formed between the extreme C terminus of DrrA and the N terminus of DrrB, which is 
described in the next section.  Interestingly, it was also found that Y89C traps DrrA in the ho-
modimeric state, indicating that Q-loops from the opposing subunits are in close proximity in the 
closed conformation of the NBD dimer of DrrA [16].  However, the conformation of the Y89C-
Y89C dimer was shown to be different from that in the strain containing both Y89C and S23C.  
Using disulfide cross-linkers of different arm lengths, it was shown that the presence of S23C in 
DrrB produces changes in conformation of the Y89C-mediated DrrA dimer, making it more rigid 
and probably more potent for ATP-binding.  It was thus proposed that the NBD dimer is normal-
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ly in a flexible contact until a conformational change in DrrB (mimicked by S23C substitution in 
this situation) produces a consequent change in DrrA that fixes the NBD dimer in the closed 
state.  This conformational change may resemble the transient state in which the signal of doxo-
rubicin binding to DrrB is transmitted to the NBD and induces formation of the closed NBD di-
mer [16].    
The C-terminal 132 amino acid domain of DrrA contains novel motifs involved in interac-
tion with DrrB and function of the DrrAB complex 
Recently a spate of studies has revealed that the C-terminal extensions of the NBD com-
ponents of ABC proteins may contain important functions, which makes this region emerge as an 
essential regulatory apparatus for substrate translocation [20-28].  The amino acid sequence of 
this region of ABC proteins is not highly conserved except in closely related proteins, however a 
structural similarity has been observed in these regions based on the 3-dimensional analysis of 
some ABC proteins [20-22].  DrrA also contains a unique C-terminal extension that covers the 
last 132 amino acid residues (residue 199-330).  Since this region is organized separately from 
the conventional NBD motifs which are present in the N-terminal domain of DrrA, it is reasona-
ble to propose that it carries out a specific function other than direct ATP binding and hydrolysis.  
 Since the function of the C-terminal region of DrrA has never been studied before, the 
present study set out to find out whether this region contains motifs that are specifically im-
portant for function of the transporter.  In this dissertation, three novel motifs, GATE, DEF (re-
ferred to as LDEVFL in Chapter 1) and CREEM, were identified in the C-terminal 132 amino 
acid domain of DrrA.  Of these, DEF (302-SLDEVFLALTGH-313) and CREEM (321-
EEAAEEEKVA-330), present at the extreme C terminus of DrrA, were found to be conserved in 
other prokaryotic and eukaryotic proteins of the DRA family of ABC proteins to which the 
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DrrAB system belongs.  The most noteworthy among these are the ABCA subfamily proteins 1, 
2, 3 and 8, which are primarily involved in lipid trafficking and homeostasis in mammalian cells 
[29].  Interestingly, disulfide cross-linking studies showed that the CREEM motif, together with 
its immediate upstream region up to residue S319, exhibits strong interaction once again with the 
N-terminal cytoplasmic tail region of DrrB, whereas the DEF motif regulates this interaction and 
therefore possibly the assembly and function of the DrrAB complex.  The present study, there-
fore, defines a second interaction interface between the extreme C terminus of DrrA and the N 
terminus of DrrB. 
The third novel motif referred to as ‘Glycine-loop And Transducer Element’ (GATE) was 
found to be conserved not only among close homologs of the DRA family, but is also found in 
diverse ABC proteins, including MalK, ModC, BtuD, Pgp, Cystic fibrosis transmembrane con-
ductance regulator (CFTR), MsbA, and Sav1866.  Based on our biochemical analyses, three 
highly conserved glycines in this motif were found to be indispensible for conferring the neces-
sary flexibility for proper integrity and function of the complex.  The analysis of the MalK crys-
tal structure and the DrrA model suggested that one of these glycines, G215, forms hydrogen 
bonds with important residues in the Walker A motif which have direct interactions with ATP, 
indicating that G215 may be involved in ATP binding and/or catalysis.  Additional structural 
studies further suggest that GATE may function as a transducer of conformational changes dur-
ing the catalytic cycle of DrrAB the complex.  Specifically, G215 may be able to sense the con-
formational changes resulting from ATP binding to Walker A, and another essential residue 
K227 in the GATE domain may then be able to transduce those changes to DrrB through its in-
teraction with S319 in the extreme C terminus of DrrA. 
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The present work, therefore, revealed the presence of two distinct functional modules in 
the C-terminal region of DrrA and provided valuable insights for two of the most important as-
pects underlying the mechanism of the DrrAB transporter.  First, these studies showed that the 
two motifs present in the extreme C terminus of DrrA are involved in interaction with DrrB, 
which may facilitate proper assembly and function of the complex.  Second, the GATE domain 
located between the N- and the C- terminal domains of DrrA may be crucial for mediating signal 
transduction and communication between DrrA and DrrB during catalysis.  The conservation of 
these motifs among other members of the ABC family suggests that they may play similarly im-
portant roles in the other ABC proteins.  
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CHAPTER 1 
THE EXTREME C TERMINUS OF THE ABC PROTEIN DrrA CONTAINS 
UNIQUE MOTIFS INVOLVED IN FUNCTION AND 
ASSEMBLY OF THE DrrAB COMPLEX 
1.1 Introduction 
Membrane proteins play vital roles in critical biological systems, which include solute transport, 
signal transduction, and energy conservation.  Loss of function, or misassembly, of membrane 
proteins is frequently associated with severe medical conditions.  However, due to the many hur-
dles involved in the study of these proteins, assembly and function of membrane protein com-
plexes is still poorly understood.  Moreover, diverse mechanisms and factors (both extrinsic and 
intrinsic) can contribute to localization and assembly of membrane proteins (1,2), thus making 
the analysis of this process quite challenging.  We are interested in elucidating the function of the 
DrrA and DrrB proteins of Streptomyces peucetius, which together form an ATP-driven efflux 
pump for doxorubicin and daunorubicin, two antibiotics used in the chemotherapy of cancer.  
DrrA belongs to the ABC family of proteins and forms the catalytic subunit (3,4), while DrrB is 
an integral membrane protein containing eight transmembrane -helices (5). Therefore, in this 
system, the catalytic function and the membrane transport function are present on separate subu-
nits, which form a tetrameric complex and carry out doxorubicin efflux.  Some other ABC trans-
porters, such as P-glycoprotein (Pgp) and cystic fibrosis transmembrane conductance regulator 
(CFTR), contain two nucleotide binding domains (NBDs) and two transmembrane domains 
(TMDs) fused together into a single, large polypeptide (6). 
Previous studies have shown that DrrB is improperly assembled in the absence of DrrA.  
In this situation, DrrB is either quickly degraded (7) or, if overexpressed, it severely inhibits 
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growth (4), implying that interaction with DrrA is essential for stability, and perhaps also for 
proper conformation of DrrB (7). Recent studies have shown that DrrA and DrrB proteins confer 
doxorubicin resistance only when the two proteins are expressed in cis in a translationally cou-
pled manner (8).  It is thus likely that the DrrA and DrrB proteins may be required to co-fold for 
the formation of a fully functional DrrAB complex, and translational coupling may facilitate this 
interaction.  This raises the question: is a specific interaction between DrrA and DrrB involved in 
the assembly process?  Here we show that the C terminus of DrrA indeed contains two novel 
motifs, which play a critical role in function and assembly of the DrrAB complex.  One motif 
present at the extreme C terminus of DrrA is rich in glutamic acid residues and is termed the ‘C-
terminal Regulatory E-rich Motif (CREEM)’ in this study.  The second motif, termed LDEVFL, 
is located upstream of the CREEM motif.  Interestingly, by homology sequence comparisons, 
these two motifs were found to be conserved in other prokaryotic and eukaryotic ABC proteins, 
the most noteworthy among these being the ABCA subfamily proteins 1, 2, 3, and 8, as well as 
Ced-7, which belong to the same family (DRA) of ABC proteins as DrrAB (9).  ABCA proteins 
are involved in lipid efflux in mammalian cells, and defects in the function or assembly of pro-
teins of this subfamily are associated with severe medical conditions, including Tangier and Alz-
heimer’s diseases (10,11). 
Recently, a spate of investigations has reported that the C-terminal domains of some 
ABC proteins may be associated with specialized functions.  The amino acid sequence of the C-
terminal domains is, however, only conserved among closely related proteins.  For example, a 
vast majority of binding protein-dependent sugar transport systems harbors a ~150 amino acid 
long C-terminal extension containing three conserved regulatory motifs termed RDM1-3 (12,13).  
In MalK of Escherichia coli, this region binds MalT and EIIglc and plays a key role in regulation 
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of expression (14,15) and in inducer exclusion (12,16).  Of the non-sugar ABC transporters, the 
C-terminal regulatory domain present in ModC of the molybdate/tungstate transporter (Ma-
ModBC) in Methanosarcina acetivorans binds molybdenum and is involved in trans-inhibition 
of the ATPase activity, which results in a decrease of the transport rate in response to an increase 
in concentration of the substrate in the cytoplasm (17).  Similarly, C-terminal extensions present 
in MetN of the MetNI system (18) and in Wzt of the Wzt/Wzm system of E. coli are able to bind 
their respective pump substrates (19,20). Crystal structure analysis suggests that the C-terminal 
domains of these proteins contain a similar β-sheet fold, though they contain diverse amino acid 
sequences and perform different functions in ABC transporters. 
In the studies described here, we report that the CREEM and LDEVFL motifs present in 
the extreme C terminus of DrrA are critical for function of the DrrAB complex.  We also show 
that this region of DrrA forms the point of contact with the N-terminal cytoplasmic tail of DrrB, 
thus leading to the proposal that the major role of the CREEM and LDEVFL motifs may be in 
assembly of the DrrAB complex. Interestingly, a 33 amino acid region in the C terminus of 
DrrA, encompassing residues in the LDEVFL motif, was also found to be involved in homodi-
merization of DrrA.  The significance of these two interactions, both localized to the C-terminal 
end of DrrA, in protein assembly is discussed.   
1.2 Materials and methods 
Bacterial strains, plasmids, and antibodies- The bacterial strains used in this study were E.coli 
TG1, N43, LE392ΔuncIC, HMS174, and XL1-Blue. The plasmids used in this study include 
pDx101 (drrAB in pSU2718) and pDx119 (drrAB in pET 16b).  Various substitutions and dele-
tions were created in the drrA and drrB genes in these plasmids.  Rabbit polyclonal antibodies, 
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generated against DrrA and DrrB previously (4), were used for Western blot analysis.  Anti-
SecY antibody was provided by the laboratory of Dr. P.C. Tai.  
Media and growth condition- For doxorubicin efflux experiments, cells were grown in TEA 
medium [50 mM triethanolamine HCl (pH 6.9), 15 mM KCl, 10 mM(NH4)2SO4, 1 mM MgSO4] 
supplemented with 0.5 % (w/v) glycerol, 2.5 µg/ml thiamine, 0.5 % (w/v)  peptone, and 0.15 % 
(w/v) succinate at 37°C(21). For site-directed mutagenesis, XL1-Blue cells were grown at 37°C 
in NYZ+ broth [pH 7.5, 1% (w/v) casein hydrolysate, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl] supplemented with 12.5 mM MgCl2, 12.5 mM MgSO4 and 0.4% (w/v) glucose (La Jolla, 
CA).  For all the other experiments, cells were grown in LB medium. Chloramphenicol was add-
ed to 20 μg/ml, and ampicilin was added to 75 μg/ml, where needed. 
Site-directed mutagenesis of DrrA- A QuikChange multisite-directed mutagenesis kit (La Jolla, 
CA) was used to create various mutations in the drrA gene.  The strategy involved the use of 
complementary primers that incorporated the change at the required position. 
Mutagenesis of residues in the LDEVFL and CREEM motif- pDx101 was used as a template. 
Primers were designed as described before (22).  In the LDEVFL motif, conservative point muta-
tions at positions 303 and 304 were created, which were named L303V and D304N, respectively.  
Besides, two sets of triple alanine substitutions were performed at 306, 307, 308 and 310, 311, 
312, resulting in V306A/F307A/L308A and L310A/T311A/G312A, respectively. Deletion of the 
LDEVFL motif was obtained by using a pair of primers consisting of 15 flanking bases on each 
side of the sequence to be deleted, and the resulting clone has been designated ∆LDEVFL.  In 
the CREEM motif, 3, 4 or 5 glutamic acid residues, present within the last 10 amino acid region 
of DrrA, were altered to glutamine, aspartic acid or glycine residues.  The obtained mutants in-
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clude E(321, 322, 325)D,  E(321, 322, 325)G, E(321, 322, 325, 326)Q and E(321, 322, 325, 326, 
327)G, which are referred to as 3E-3D, 3E-3G, 4E-4Q and 5E-5G, respectively. 
Single cysteine substitutions in DrrA- pDx101 containing a single cysteine substitution in drrB at 
position 23(S23C)was used as the template (22). Single cysteine substitution mutants were creat-
ed at amino acid positions 325, 323, 319, 311, 302, 287, 253 or 232 in DrrA in this clone.  
Deletion of the C terminus of DrrA- This was achieved by removing 27 bases (960-987) from 
the 3’ end of drrA while retaining the last 3 bases of the sequence in order to maintain transla-
tional stop/start overlap with drrB. An XhoI site was first introduced in the 3’ end of drrA by 
substituting 3 bases at positions 963, 966 and 968 in pDx101. These changes did not alter the 
coding sequence of drrA. The sequence of the primers used was: 
UP-XhoI: 5’-GCCGATGACCGCTCGA 
GGGAAGAAGCG-3’, 
DN-XhoI: 5’-GCTTCTTCCCTCGAGC 
GGTCATCGGC-3’. 
This construct was designated pDx137. pDx137 DNA was then digested with XhoI (at 
960th nucleotide in drrA) and FseI (at 84th nucleotide in drrB) to remove 139 bp fragment from 
the intergenic region of drrAB.  A fragment corresponding to this region was then synthesized 
by mutually primed synthesis using single-stranded oligonucleotides.  The oligonucleotides, 
which are shown below, were designed such that 27 base pairs of drrA will be deleted from the 
synthesized fragment.  The flanking regions contained XhoI and FseI restriction sites. 
Spacer27delUP: 
5’GCCGATGACCGCTCGAGGGCATGACGACGTCCCCCGGCACCGTGGAATCCA
CGACCCCTGTGAGCGGTCAGC3’, 
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Spacer27delDN: 
5'CCGTCGCGCGGGCCGGCCGTTCACCCGCGGACAGCACCGTCCGCAGCTGAC
CGCTCACAGGGGTCGTGGATT3'. 
The 112 bp fragment was digested with XhoI and FseI and then ligated to pDx137 DNA 
that had been digested with the same enzymes.  The resulting clone has been designated 
∆CREEM. 
Doxorubicin resistance Assay- Doxorubicin resistance assays were carried out as described ear-
lier (23).  Briefly, the indicated plasmids were transformed into E.coli N43 cells which are doxo-
rubicin sensitive.  A single colony was incubated in 5ml LB containing desired antibiotic for 8 
hours.  1 μl of the above cells were streaked on M9 plates with a top layer containing 0, 4, 6, 8 or 
10 μg/ml doxorubicin.  Plates were covered with foil because doxorubicin is light sensitive.  
Growth was recorded after incubation of plates at 37°C for 24 hours. 
Doxorubicin efflux assay- The efflux assay was carried out according to the protocol previously 
developed in this laboratory (Sharma and Kaur, unpublished). Briefly, E. coli LE392ΔuncIC 
cells (24) were transformed with the indicated plasmids; the cells were grown to mid-log phase 
(optical density 600 nm = 0.6) and induced with 0.1 mM IPTG for 1 hour, harvested and washed 
with TEA twice and resuspended in 1 ml of TEA.  10 l of the cell suspension from above was 
incubated in 3 ml of TEA medium containing 10 µM doxorubicin and 5 mM 2, 4-dinitrophenol 
(DNP) for 11 hours at 37°C.  The loaded cells were washed twice with 0.1 M MOPS buffer, pH 
7.0, containing 2.0 mM MgSO4 and resuspended in 3 ml of MOPS buffer.  The fluorescence 
spectra were recorded on an Alphascan-2 spectrofluorometer (Photon Technology International, 
London, Ontario, Canada).  The excitation wavelength for doxorubicin was 480 nm and emission 
was monitored at 590 nm. The excitation and emission slit widths were set at 0.75 and time 
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based script was run.  After an initial recording of fluorescence for 100 seconds at 37°C, energy 
was provided in the form of 20 mM glucose and recording was continued for an additional 400 
seconds. 
Preparation and analysis of cell membranes- 50 ml E.coli TG1 cells containing the indicated 
plasmids were grown to mid-log phase and induced with 0.1 mM IPTG. Growth was continued 
for an additional 3 h at 37°C. The membrane fraction was prepared as following: cells were spun 
down and resuspended in 10 ml buffer A [25 mM Tris-Cl (pH7.5), 20% glycerol, 2 mM EDTA 
(pH8.0), 1 mM DTT] and passed through a French Press cell at 16,000 psi, followed by centrifu-
gation at 10,000 g at 4°C for 30 min to remove unbroken cells. The supernatant was centrifuged 
at 100,000 g at 4°C for 1 hour. The pellet was resuspended in 10 ml buffer A, washed twice, and 
finally resuspended in 100 µl buffer A.  The samples were heated at 55°C for 10 min and loaded 
on 10% SDS-polyacrylamide gel.  The proteins were transferred onto the nitrocellulose mem-
brane for 2h at 55V at room temperature, followed by Western blot analysis or autoradiography. 
Densitometric scanning of the bands in both the autoradiogram and the Western blots was per-
formed by Multi Gauge V2.3 (FUJIFILM).  
ATP bindng assay- Photolabeling of DrrA with [α-32P] ATP was carried out in membranes con-
taining wild type DrrAB or DrrAB bearing mutations in DrrA (23). ATP binding assay was car-
ried out in a 100 µl reaction system containing buffer A, 0.1 mg membrane protein, 10 µM ATP 
(pH7.5), 10 µCi α-32PATP, 35 µM doxorubicin and 5mM MgCl2. The reaction was exposed to 
UV light at 254 nm on ice for 30 min, followed by protein precipitation by 10% ice-cold TCA on 
ice for 30 min. Protein was recovered by centrifugation at 14,000 g for 15 min and the pellet was 
resuspended into 20 µl of 4X Laemmli sample buffer and 5 µl 1M unbuffered Tris. The samples 
were resolved by polyacrylamide gel electrophoresis and transferred onto nitrocellulose mem-
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brane, as described in the previous section.  The membrane was air-dried and exposed to X-ray 
film at -70°C overnight, followed by autoradiography.  The same blot was then examined by 
Western blot using anti-DrrA antibody. 
Disulfide cross-linking- A 100 μl reaction volume containing 250 μg of membrane protein in 
0.1M phosphate buffer pH 7.4 (0.1M of Na2HPO4 and 0.1M NaH2PO4) was treated with thiospe-
cific reagents including copper phenanthroline (CuPhe, 3 mM CuSO4/9 mM 1, 10-
Phenanthroline) or 1 mM dithio-bis-maleimidoethane (DTME, Pierce Chemicals). The cross-
linking reaction was carried out at room temperature for 30 min and stopped by adding 4X 
Laemmli sample buffer.  A 25 μl portion (50 μg of membrane protein) of the reaction mixture 
was then analyzed by 10% SDS-polyacrylamide gel, followed by Western blot analysis using 
anti-DrrA or anti-DrrB antibodies. 
Co-purification of DrrA and DrrB- pDx119-derived clones bearing different mutations in DrrA 
were used for co-purification of DrrAB proteins.  HMS174 cells containing the indicated plas-
mids were grown to mid-log phase at 37°C.  The expression of DrrAB was induced with 0.1 mM 
IPTG at 20°C and growth was continued for 16 hours at 20°C.  DrrAB proteins were solubilized 
from 5 mg membrane fraction with 5 ml solubilization buffer [50 mM Tris-Cl (pH7.5), 1% n-
dodecyl-β-D-maltoside (DDM), 1µl 14.3 M β-mercaptoethanol, 20% glycerol, 200 mM NaCl] 
on ice for 1h.  After centrifugation at 100,000 g at 4°C for 1 hour, the supernatant was loaded on 
a Ni-NTA column at 4°C. The DrrAB proteins were eluted with the buffer containing 50 mM 
Tris-Cl (pH7.5), 300 mM NaCl, 20% glycerol, 0.05% DDM and 500 mM imidazole at 4°C.  The 
purified proteins were resolved on 12% SDS-polyacrylamide gels and analyzed by Western blot 
using anti-DrrA or anti-DrrB antibodies. 
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Modeling analysis-     AMMP protein structure modeling software ((26),   
http://asterix.cs.gsu.edu/ammp.html) was used for homology modeling of DrrA and its mutants 
using the crystal structure of MalK (PDB ID: 2R6G; (25)) as a template.  Modeling analysis of 
the membrane protein DrrB was carried out using PHYRE protein fold recognition server ((27), 
http://www.sbg.bio.ic.ac.uk/phyre/) since DrrB is not homologous to the MalG or MalF protein 
or another crystallized membrane protein of the ABC family.  The models of DrrA and DrrB 
complexes were then created by using Rosetta Dock protein-protein docking server ((28), 
http://rosettadock.graylab.jhu.edu/).  Please note that docking analysis requires that the investiga-
tor provide a reasonable starting position for docking of two proteins.  Based on the biochemical 
data presented in this paper, we provided the starting position where the relevant portion of the C 
terminus of DrrA and the N terminus of DrrB faced each other.  Using this starting position, the 
Rosetta Dock server modeled the wild type and mutant DrrAB complexes.  PyMOL Molecular 
Graphics System ((29), http://www.pymol.org/) was used to view all the predicted structures and 
for presentation of the models. 
1.3 Results 
A glutamic acid-rich sequence at the extreme C terminus of DrrA is required for function of 
the DrrAB complex- DrrA belongs to the ABC family of proteins and contains all the known 
conserved motifs (including Walker A, Walker B, Q-loop, signature, and switch motifs) required 
for the catalytic function of ABC proteins.  These motifs are confined to the N-terminal domain 
of DrrA (residues 41-198)(23)(Fig. 1.1A), while the C-terminal domain (residues 199-330) is not 
known to contain any conserved motifs involved in function or assembly.  In this study, we iden-
tified a glutamic acid-rich sequence (EEAAEEEKVA) at the extreme C terminus of DrrA, which 
suggested the possibility that the negatively charged residues present in this region may be in-
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volved in interaction between DrrA and DrrB.  To determine the role of this region, last 9 amino 
acids (residues 321-329) of DrrA were deleted, but the overlapping sequence between the trans-
lational stop of DrrA and the start of DrrB was retained.  This truncation reduced the expression 
of DrrA and DrrB to roughly 55% and 78% of the wild type, respectively (Fig. 1.1B, lane7, and 
Figs. 1.1C and 1.1D).  Doxorubicin resistance was severely compromised in this strain (Table 
1.1). One explanation for these data could be that this region may play a role in stability of DrrA; 
however,  when site-directed substitutions of 3, 4 or 5 glutamates with aspartates, glycines or 
glutamines were carried out (resulting in 3E-3D, 3E-3G, 4E-4Q and 5E-5G, as described in 
Methods), the expression level of DrrA and DrrB remained about the same as in wild type cells 
(Fig. 1.1B, lanes3-6 and Figs. 1.1C and 1.1D).  Doxorubicin resistance in the strain containing 
5E-5G mutation was found to be drastically affected, whereas it was only partially compromised 
in strains containing substitutions of three or four glutamates (Table 1.1).  Together, the deletion 
and mutagenesis data indicate that the glutamic acid-rich region in the extreme C terminus of 
DrrA is important for function, and suggest that it may play a role in DrrA-DrrB interaction and 
assembly of the complex.  This region has been termed ‘C-terminal Regulatory E-Rich Motif 
(CREEM)’ in this study.  Further characterization of this motif is described in later sections. 
The extreme C terminus of DrrA interacts with the N-terminal cytoplasmic tail of DrrB- To 
determine if the extreme C terminus of DrrA interacts with DrrB, disulfide cross-linking experi-
ments were performed.  Previous studies, using a cysteine to amine cross linker GMBS, have 
shown that the N–terminal cytoplasmic tail of DrrB (residues 1-53) is the region that contacts 
DrrA (22).  To determine if the extreme C terminus of DrrA is the region that makes the above 
contact with the N-terminal tail of DrrB, cysteine substitutions were created in these two do-
mains.  Residue S319 (immediately upstream of the CREEM motif) (Fig. 1.1A) was selected for 
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the first cysteine substitution in DrrA, and it was tested in conjunction with a substitution S23C 
within the N-terminal tail of DrrB.  This construct was termed A(S319C)B(S23C) to stress the 
location of the cysteines.  (Note that all the cysteine substitution mutants were named as above, 
unless mentioned otherwise).  Strikingly, when membranes containing A(S319C)B(S23C) were 
treated with homobifunctional (disulfide) cross-linkers, CuPhe (arm length: 0Å) or DTME (arm 
length: 13.3Å), a species migrating at 65kDa, which was previously identified as the size of 
DrrA-DrrB heterodimer (22), was detected by anti-DrrA antibody (Fig. 1.2A, lanes 4 and 5).  
The same species was also detected by anti-DrrB antibody (Fig. 1.2B, lanes 4and5), which im-
plies the formation of DrrA-DrrB heterodimer.  These data suggest that the extreme C terminus 
of DrrA and the N-terminal tail of DrrB are in close proximity and they interact with each other, 
highlighting the significance of this region of DrrA in mediating the association between the 
NBD and the TMD of this ABC transporter.  To verify the specificity of this interaction, the 
same cross-linking experiments were carried out with A(S319C)B(C260), which contains the 
native cysteine at position 260 in DrrB.  DrrA-DrrB heterodimer was not formed in this situation, 
implying that residue 319 in DrrA specifically contacts the N-terminal tail of DrrB (Figs. 1.2A 
and 1.2B, lanes 6-8). 
Two minor species of higher molecular mass (roughly 72kDa, marked with an oblique ar-
row in Fig. 1.2A) were also identified by anti-DrrA antibody in CuPhe-treated 
A(S319C)B(S23C) membranes (Fig. 1.2A, lane 4).  Since these species were not detected by an-
ti-DrrB antibody, they are likely to be DrrA homodimers, and they correspond in size to the ex-
pected size of the DrrA dimer.  Interestingly, these potential DrrA homodimeric species become 
the major cross-linked species in membranes containing A(S319C)B(C260)(Fig. 1.2A, lane 7), 
when no cysteine is present in the N-terminal tail of DrrB.  We have previously shown that DrrA 
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is trapped in a homodimeric conformation when a cysteine (Y89C) is introduced into the Q-loop 
of DrrA (23)(also shown in Fig. 1.2A, lane 2, marked with a horizontal arrow).  This event re-
flects the head-to-tail dimerization of the N-terminal catalytic domain of DrrA as well as other 
ABC proteins (30-32). The DrrA homodimer produced by Y89C-Y89C cross-linking is slightly 
bigger in size (78 kDa)than the S319C-S319C species, which is likely due to different confor-
mations of the DrrA dimer produced in these two situations.  Furthermore, these two dimeriza-
tion events are likely to be distinct; previous studies showed that Y89C-mediated dimerization of 
DrrA is affected by ATP (23), whereas S319C-mediated dimerization is not influenced by ATP 
(data not shown).  A species marked as B+B, which corresponds to the size of DrrB homodimer, 
was also produced in membranes containing either S23C or C260 (Fig 1.2B, lanes 4, 5, 7 and 8).  
Since this species is produced in all cysteine-containing DrrB variants (22), it is likely to be the 
result of non-specific association between cysteines in DrrB. 
To further define the DrrA-DrrB contact region within the C terminus of DrrA, single 
cysteine substitutions were introduced both upstream and downstream of residue S319 in DrrA 
in a strain already containing S23C as the only cysteine in DrrB.  Two downstream cysteines in-
troduced within the CREEM motif, A323C and E325C, showed high efficiency of disulfide 
cross-linking with S23C (Fig. S1.1), as seen previously between S319C and S23C (Fig. 1.2).  
Analysis of the cysteine substitutions upstream of S319 (at residues 311, 302, 287, 253 or 232) 
provided different results.  In membranes containing A(T311C)B(S23C), two cross-linked spe-
cies were detected: a minor species of DrrA-DrrB heterodimer identified by both anti-DrrA and 
anti-DrrB antibodies and a major DrrA dimeric species detected by only anti-DrrA antibody 
(Figs. 1.3A and 1.3B, lanes 7and8).  The major species is similar to the 78 kDa DrrA homodimer 
seen in A(Y89C)B(S23C)(Fig. 1.3A, lane 2).  As the location of cysteine substitution moved fur-
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ther away from the C-terminal end of DrrA, for example in A(S302C)B(S23C) or 
A(S287C)B(S23C), DrrA-DrrB heterodimer was undetectable and only DrrA homodimer for-
mation was observed (Figs. 1.3A and 1.3B, lanes 9-14).  In A(S253C)B(S23C) or 
A(S232C)B(S23C), neither DrrA-DrrB heterodimer nor the DrrA homodimer was seen (Figs. 
1.3A and 1.3B, lanes 15-20).  Taken together, the results discussed above suggest that the ex-
treme C terminus of DrrA participates in two interactions; the region containing the CREEM mo-
tif, up to residue S319, is involved in DrrA-DrrB heterodimerization, whereas the 33-residue re-
gion upstream of S319 (287 to 319) is involved in DrrA homodimerization.  Interestingly, resi-
due 319 is involved in both DrrA-DrrA and DrrA-DrrB interactions, even though the DrrA-DrrB 
interaction between S319C and S23C is preferred, as seen in Figs. 1.2A and 1.2B. 
The C-terminal domain of DrrA contains conserved motifs- To determine if the sequence of the 
C-terminal domain of DrrA is conserved, last 132 amino acids (residue 199-330), located right 
after the switch motif, were subjected to NCBI Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
Surprisingly, this search picked up 99 bacterial and archaeal ABC members.  All of these pro-
teins are ABC components of putative doxorubicin or multidrug resistance ABC transporters 
from various phyla.  Even though most of these proteins remain uncharacterized, based on their 
homology with DrrA it is likely that they belong to the DRA family of ABC proteins.  A multi-
ple sequence alignment of all 99 homologs using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) strongly pointed out two highly conserved 
regions, which we have named LDEADQLA and LDEVFL in this study (Fig. S1.2).  The 
LDEADQLA motif covers 29 residues (199-227), while the LDEVFL motif contains 12 residues 
(302-313).  These motifs are named according to the sequence of the amino acid residues in 
these motifs, and their location in DrrA is marked in the schematic presented in Fig. 1.1A.  Eight 
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out of the 99 homologs also exhibited a glutamic acid-rich sequence in their extreme C termini, 
which was defined as CREEM in DrrA in a previous section.  These members were, therefore, 
chosen for a separate multiple sequence alignment using the last 30 amino acid region of these 
proteins.  This alignment highlights both the LDEVFL and the CREEM motifs in this group of 
proteins (Fig. 1.4A).  In summary, we find that the LDEADQLA and LDEVFL motifs are highly 
conserved in DrrA and all members identified by the Blast search.  However, the CREEM motif 
is conserved in only a few members, which might indicate that CREEM plays a more specific 
role in function of only some of these transporters. 
Interestingly, when a TC-Blast analysis (based on the Transport Classification Database 
(TCDB, http://www.tcdb.org/progs/blast.php) of the last 132 amino acid sequence of DrrA was 
performed, it identified mostly eukaryotic homologs, which included ABCA1, ABCA2, ABCA3 
and ABCA8 from Homo sapiens(and other mammals) and cell death protein 7 (Ced-7) from 
Caenorhabditis elegans.  These eukaryotic proteins are evolutionarily more closely related to 
bacterial proteins, DrrA and NodI, than to the eukaryotic ABC transporters (33) and are assigned 
to the same family (DRA), but to different subfamilies (DRR and ABCA, respectively) of ABC 
exporters (9,34).  Like most other eukaryotic members of the ABC superfamily, ABCA proteins 
contain two NBDs and two TMDs within a large molecule (35).  DrrA sequence was, therefore, 
aligned with the corresponding region in NBDI or NBDII of these homologs.  It was found that 
both the NBDI and NBDII of these proteins contain the conserved LDEADQLA and LDEVFL 
motifs (Figs. S1.3 and S1.4).  Only ABCA2 was, in addition, also seen to contain the CREEM 
motif, which is highlighted by a manual alignment of the last 29 residues of DrrA with the corre-
sponding region of three ABCA2 isoforms from different species (Fig. 1.4B).  Taken together, 
the above analyses allowed the identification of three conserved motifs, LDEADQLA, LDEVFL 
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and CREEM, within the C-terminal domain of DrrA.  Two motifs, LDEVFL and CREEM, at the 
extreme C terminus of DrrA, were selected for further characterization, as described below. (For 
clarity, the usage of term ‘extreme C terminus’ in this manuscript refers to the last 50 amino ac-
ids and includes both CREEM and LDEVFL motifs of DrrA) 
The conserved motifs in the extreme C terminus of DrrA are involved in function and assem-
bly- Point mutations and deletions of the conserved residues in the LDEVFL and CREEM motifs 
were created through site-directed mutagenesis.  Mutations created in the LDEVFL motif include 
L303V, D304N, V306A/F307A/L308A (three residues simultaneously mutated to alanine), 
L310A/T311A/G312A, and ∆LDEVFL (residues 302-313 were deleted).  Mutations in the 
CREEM motif, as described earlier, include 3E-3G, 3E-3D, 4E-4Q, 5E-5G, and ∆CREEM (resi-
dues 321-329 were deleted).  Effect of these mutations on expression of the DrrA and DrrB pro-
teins, ATP-binding to DrrA, doxorubicin resistance, as well as doxorubicin efflux was studied.  
Furthermore, effect of these mutations on interaction between DrrA and DrrB was examined by 
disulfide cross-linking experiments. Co-purification of DrrA and DrrB on Ni-NTA resin was 
used as an indicator of assembly of native DrrAB complexes. These studies are described in the 
sections below. 
Effect of mutations in LDEVFL and CREEM on expression of DrrA and DrrB- Western blot 
analysis of the membrane fractions generated from the mutants described above showed that the 
average DrrA and DrrB expression varied between 80-100% in the different point mutants in the 
CREEM and LDEVFL motifs (Figs. 1.1B-D; Figs. 1.5A-C), therefore suggesting that these mo-
tifs do not play a significant role in stable maintenance of DrrB in the membrane.  The strain 
containing ∆CREEM, however, showed an average reduction of 55% and 78%, respectively, for 
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DrrA and DrrB (Figs. 1.1B-D), which is most likely due to deletion of multiple residues in this 
motif.  
Effect on ATP-binding to DrrA- UV-induced [α-32P] ATP binding to DrrA was analyzed, as de-
scribed under Methods.  The data in Figs. 1.6A and B, upper gels, represent autoradiograms 
showing ATP binding, while the lower gels show Western blot analysis of the same blots with 
anti-DrrA antibodies.  The ATP binding efficiency of the wild type DrrA and each mutant was 
calculated as the ratio of ATP bound (in the presence of doxorubicin) to the amount of DrrA in 
the sample.  The efficiency of ATP binding was then plotted in a histogram designating the effi-
ciency of wild type as 1 (Fig. 1.6C).  (Please note that the gels shown in Fig. 1.6A and B are rep-
resentative, and the data in Fig. 1.6C reflect average of three independent experiments.) Surpris-
ingly, ATP-binding to L303V, V306A/F307A/L308A, L310A/ T311A/G312A or ∆LDEVFL 
was found to be abolished both in the absence and presence of doxorubicin (Figs. 1.6A and C), 
indicating that the residues in the LDEVFL motif are critical for both basal and doxorubicin-
stimulated nucleotide binding to DrrA.  The D304N mutant was, however, unaffected (Figs. 
1.6A and C).  In the CREEM motif, 3E-3G, 3E-3D, and 4E-4Q showed normal ATP binding, 
whereas ATP binding to 5E-5G or ∆CREEM was significantly reduced (Figs. 1.6B and C).  To-
gether, these results indicate that the conserved motifs in the C terminus of DrrA influence ATP 
binding in a significant manner.  
Effect on doxorubicin resistance- Mutations described above were also found to have a signifi-
cant effect on the overall function of the efflux pump (Table 1.1).  It was found that L303V, 
V306A/F307A/L308A, L310A/T311A/G312A and ∆LDEVFL mutations confer doxorubicin 
sensitivity in the cells, whereas the D304N mutation has only a minor effect on doxorubicin re-
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sistance. Mutations in the CREEM motif affected doxorubicin resistance to varying degrees, with 
5E-5G and ∆CREEM having the most drastic effect (Table 1.1).   
Effect on doxorubicin efflux- To further confirm the importance of LDEVFL and CREEM mo-
tifs in function, doxorubicin efflux by the DrrAB proteins bearing above mutations was tested.  
Doxorubicin is fluorescent in solution, however its fluorescence is quenched on binding to DNA 
inside the cells.  This property was used to measure doxorubicin efflux in E. coli cells expressing 
DrrA and DrrB.  Efflux was initiated by providing glucose to preloaded E. coli cells, and the re-
sulting increase in doxorubicin fluorescence was recorded.  The rate of efflux was determined by 
calculating the slope of the linear portion of each curve shown in Figs. S1.5 A-C.  The efficiency 
of efflux in each LDEVFL or CREEM mutant was then calculated as the percentage of the mu-
tant slope/wild type slope.  Control cells containing just the vector showed about 30% efflux of 
the strain containing wild type DrrAB proteins (Table 1.2).  This basal efflux seen in control 
E.coli cells is most likely contributed by the AcrAB pump, which is known to carry out efflux of 
many different antibiotics by coupling it to the energy of proton gradients (36).  Mutations in the 
LDEVFL motif resulted in varying degrees of effect on doxorubicin efflux.  The most severe ef-
fect was seen in the L303V, V306A/F307A/L308A and ∆LDEVFL mutants, while D304N re-
mained relatively unaffected (Table 1.2).  Of the CREEM mutants, only 5E-5G mutation and 
∆CREEM showed a reduction in efflux, while 3E-3G, 3E-3D, 4E-4Q exhibited normal doxoru-
bicin efflux (Fig. S1.5C and Table 1.2; Note that the efflux curves for 3E-3D and 4E-4Q are sim-
ilar to that of 3E-3G and are not shown in Fig. S1.5C). Overall, the results of the doxorubicin 
efflux assay are consistent with the doxorubicin resistance results.  Taken together, these data 
show that both LDEVFL and CREEM motifs are essential for the function of the DrrAB trans-
porter.  Specifically, residues at positions 303, 306, 307, 308, 310, 311, and 312 in LDEVFL are 
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key residues that are indispensable for the overall function.  Glutamic acid residues in the 
CREEM motif also play an important role, even though a significant reduction in doxorubicin 
resistance, doxorubicin efflux, or ATP binding is seen only when all 5 glutamic acid residues are 
mutated. 
Effect on DrrA-DrrB interaction- To determine the role of LDEVFL and CREEM motifs in 
DrrA-DrrB interaction, each of the above mutations was introduced into a strain containing 
A(S319C)B(S23C).  Effect of each mutation on DrrA-DrrB heterodimer formation was studied 
by disulfide cross-linking between S319C and S23C, as described earlier. The intensity of the 
DrrA-DrrB cross-linked species produced by CuPhe or DTME was determined by densitometric 
scanning of the Western blots.  The efficiency of cross-linking in each mutant was then calculat-
ed as the ratio of the DrrA-DrrB heterodimer (for example, Fig. 1.7A, panel i, lane 7) to the 
DrrA monomer (from the untreated sample) in the same set (Fig. 1.7A, panel i, lane 6).  A simi-
lar calculation was done for the wild type sample containing A(S319C)B(S23C) from the same 
blot (Fig. 1.7A, panel i, lanes 3-5).  The efficiency of cross-linking was plotted in a histogram 
designating the wild type efficiency as 1 (Fig. 1.7A, panel ii).  The data in Fig. 1.7A, panels i 
and ii strongly indicate that the L303V mutation drastically reduces the efficiency of S319C-
S23C cross-linking by both CuPhe and DTME.  On the other hand, the D304N was found to 
have no effect on the cross-linking efficiency (Fig. 1.7B, panel i, lanes 6-8and panel ii).  Strik-
ingly, the formation of the DrrA-DrrB heterodimer was completely abolished in 
V306A/F307A/L308A and ∆LDEVFL mutants (Figs. 1.7C and 1.7E, lanes 6-8).  Due to the ab-
sence of the detectable DrrA-DrrB heterodimeric species in these two mutants, efficiency of 
cross-linking could not be determined.  (Note that in the strain containing ∆LDEVFL, the size of 
the DrrA monomer as well as the DrrA homodimer is smaller than the corresponding species in 
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wild type, as expected)  Finally, L310A/T311A/G312A mutant also showed significantly re-
duced cross-linking efficiency (Fig. 1.7D, panel i, lanes 6-8and panel ii).  Together, these data 
strongly suggest that the LDEVFL motif is crucial for mediating DrrA and DrrB interaction.  
Once again, residues 303, 306, 307, 308, 310, 311and 312 were found to be essential.  Since mu-
tations in these residues do not significantly affect stable expression of DrrA and DrrB, but dras-
tically affect function of the transporter and association of subunits, it can be concluded that in-
teraction between the C terminus of DrrA and the N-terminal tail of DrrB plays a specific role in 
a higher-order process, such as assembly.In ∆CREEM mutant, the cross-linking efficiency was 
reduced to between 60-80% of wild type. However, all other CREEM mutations (including 5E-
5G) exhibited wild type-like cross-linking between S319C and S23C(data not shown), indicating 
that the specific interaction between S319 and S23 in DrrB can occur independently. 
Effect on co-purification of DrrA and DrrB- Co-purification is commonly used as an indicator 
of association and assembly of protein complexes (37, 38).  To confirm the role of the C termi-
nus of DrrA in assembly of the complex, drrAB genes bearing the mutations in the LDEVFL or 
CREEM motif were sub-cloned into pET16b vector, which places a 6xHis tag at the N terminus 
of DrrA.  Co-elution of DrrA and DrrB in the same fraction during the purification process 
would suggest that these two proteins are associated with each other.  The DrrAB complex was 
solubilized from the membrane fraction with 1% DDM, followed by standard nickel affinity 
chromatography.  The elution profiles of several LDEVFL and CREEM mutants were deter-
mined, however only the elution profiles of wild type DrrAB and the LDEVFL mutants, L303V 
and D304N, are shown in Fig. 1.8A.  The data in lanes 4 and 7, panels i and ii, show that wild 
type DrrA and DrrB co-elute in two successive elution fractions, each containing 500 mM im-
idozale (labeled as fr.1 and fr.2).  The L303V mutation, however, drastically affected co-
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purification of DrrA with DrrB (Fig. 1.8A, panels i and ii, lanes 5 and 8). The D304N mutation 
showed only a minor effect (Fig. 1.8A, panels i and ii, lanes 6 and 9).  The efficiency of co-
purification of DrrA and DrrB was determined by densitometric scanning of the Western blots, 
and the ratio of DrrB to DrrA purified in each fraction was calculated.  Note that the homodimer 
of DrrB was also observed in both 500 mM fr.1 and 500 mM fr.2, and this species was also 
scanned and included in the calculation of the amount of DrrB eluted.  When plotted in a histo-
gram, the ratio of DrrB to DrrA for the wild type sample was set as 1.  The data in Figs. 1.8B and 
1.8C show that in addition to the drastic effect of L303V, other LDEVFL mutants, including 
V306A/F307A/L308A, L310A/T311A/G312A and ∆LDEVFL, also affected the ability of DrrA 
and DrrB to co-purify.  All CREEM mutants tested (including 5E-5G and ∆CREEM) exhibited 
wild type-like co-purification efficiency (data not shown), showing once again that the region 
immediately upstream of CREEM (especially residue S319) is able to associate with DrrB inde-
pendently.   
1.4 Discussion 
This article describes the identification of two unique motifs, CREEM and LDEVFL, in the ex-
treme C terminus of DrrA that may constitute a novel assembly domain for DrrAB complex in 
the membrane.  Cysteine substitution and cross-linking experiments showed that the amino acid 
residues S319-E325 (comprising of the CREEM motif and the upstream region up to S319) in-
teract specifically with the N-terminal cytoplasmic tail of DrrB.  Interestingly, mutations and de-
letions created in the LDEVFL and CREEM motifs drastically affected doxorubicin efflux and 
resistance.  Some mutations, in addition, also abolished ATP binding to DrrA.  Since these mo-
tifs lie far away from the motifs known to be critical for ATP binding to the ABC proteins, a 
drastic effect of these mutations on ATP binding was unexpected.  Moreover, several ABC pro-
33 
 
teins, including KpsT (E. coli) (39) and MJ0796 (M. jannaschii) (40,41) do not contain C-
terminal extensions, yet they carry out ATP binding successfully.  The results obtained in this 
study can be explained, however, if we consider the fact that ATP binding to DrrA occurs only 
when DrrA is in complex with DrrB (7).  Therefore, if interaction between DrrA and DrrB is dis-
rupted by mutations in either of these motifs, it could affect ATP binding to DrrA.  Interestingly, 
we also found that not all mutations in these motifs compromise ATP binding equally.  In some 
situations, mutations in the neighboring residues resulted in strikingly different effects; for ex-
ample, the L303V mutation abolished doxorubicin resistance as well as ATP binding, while the 
D304N mutation showed no effect.  Much more extensive mutagenesis analysis is, therefore, 
needed to better understand the functions of individual residues in these motifs.  The most signif-
icant finding emerging from the mutagenesis analysis conducted so far is that some mutations in 
the LDEVFL motif also prevent DrrA and DrrB interaction (judged by disulfide cross-linking) as 
well as co-purification, which are two indicators of the ability of DrrA and DrrB to form a com-
plex.  Therefore, based on the data discussed above, we propose that the CREEM motif of DrrA, 
including residues up to S319, forms an interaction module for a specific interaction between 
DrrA and DrrB, while the LDEVFL motif plays a crucial role in regulating this interaction and in 
assembly of the DrrAB complex. This is a novel, and previously uninvestigated, aspect of ABC 
protein function and biogenesis.  A number of reports have recently appeared in literature sug-
gesting that the C-terminal extensions of ABC proteins may be associated with specialized func-
tions (12-20); that the ABC proteins may play a critical role in membrane protein biogenesis has 
never been suggested or explored before.  Since the LDEVFL and CREEM motifs are conserved 
in other prokaryotic and eukaryotic homologs belonging to the DRA family, it is likely that these 
motifs will play a similar role in these homologous systems.   
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Another interesting aspect of the work presented here is the finding that the C terminus of 
DrrA also participates in DrrA homodimerization.   This function is localized in a 33 amino acid 
region upstream of S319, and it encompasses the LDEVFL motif.  Thus, two interaction inter-
faces, DrrA:DrrB and DrrA:DrrA, were found to exist in the C-terminal end of DrrA.  These 
studies also indicate that residue S319 exists in equilibrium between A-A ↔A-B, which raises a 
number of important questions.  For example, under what conditions does the equilibrium shift to 
the AB species, and vice versa?  Further, what is the relationship between DrrA dimerization lo-
calized in the C terminus vs. the head-to-tail dimerization of the N-terminal catalytic domain of 
DrrA, described by us earlier (23).  In MalK of E. coli, the regulatory C-terminal domains of 
MalK were shown to remain in contact throughout the catalytic cycle, thus inferring that the C 
terminus plays a role in stabilization of the MalK dimer (42).  Dimerization of the C terminus of 
DrrA could similarly be involved in stabilization of the DrrA dimer; however we are leaning to-
wards the possibility that this event may be transient and it may be an important prerequisite for 
DrrA and DrrB interaction.  In previous studies using general cross-linkers (such as DTSSP or 
DSP) DrrA-DrrB heterodimer was the only species detected, while DrrA dimer was never isolat-
ed (7), suggesting the transient nature of the DrrA dimer.  Furthermore, we find that residue 319 
can participate in both A-B and A-A interactions, implying that A-B and A-A species involving 
the C terminus of DrrA are formed in a mutually exclusive manner.  
Several ABC proteins, including MalK, ModC and MetN, which contain regulatory C-
terminal domains, have been crystallized recently (17,18,25). Although the C-terminal domains 
of these proteins do not share significant amino acid identity, they all show the presence of beta-
sheet-rich folds characteristic of β-barrel or β-sandwich structures.  In ModC and MetN, these 
domains are critical for binding of the specific pump substrate, resulting in trans-inhibition of 
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ATPase activity and further substrate uptake (17,18).  In the case of MalK, the C-terminal do-
main binds cytoplasmic proteins MalT and EIIglc, which plays a role in gene expression and in-
ducer exclusion, respectively .  We used the closely related bacterial homolog MalK as a (13)
template to model the structure of wild type DrrA as well as several mutants in the conserved 
LDEVFL motif, which are shown through biochemical analysis in this study to negatively influ-
ence interaction of the C terminus of DrrA with the N terminus of DrrB and drastically affect 
function of the DrrAB complex.  The model of wild type DrrA, (generated by AMMP modeling 
software (26)), indicates that the structure of the N-terminal domain of DrrA (containing the 
ABC cassette) is almost identical to the N terminus of MalK (Fig. 1.9A and 1.9B).  Such conser-
vation of structure is not unexpected given the high homology between the N-terminal domains 
of DrrA and MalK.  The C-terminal domain of DrrA exhibits a beta sheet-rich structure which is 
also similar, but not identical, to the structure of the C-terminal domain of MalK.  In the model 
of DrrA shown in Fig. 1.9B, the LDEVFL motif (shown in yellow) is partially present in beta 
strand 6, while most of this motif is present in a loop region. Similarly, the CREEM motif 
(shown in purple) is also seen in a coil or loop region in this model.   
Modeling analysis of mutations in the LDEVFL motif, which include L303V, X306-
308A, and ∆LDEVFL, showed varying degrees of structural alterations in the C-terminal domain 
of DrrA (Fig. 1.9C-F).  Importantly, however, the structure of the N-terminal domain of DrrA 
remained largely unaltered in all mutants.  Overall, the severity of structural changes observed in 
the C-terminal domain co-related well with the biochemical effects of mutations reported earlier 
in this article.  For example, D304N mutation which showed minimal effects on DrrAB interac-
tion and function, showed no significant change in the structure of the N- or the C-terminal do-
main of DrrA (Fig. 1.9C).  In the L303V mutant, which significantly affected interaction and 
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function, beta strands 1 (shown in slate blue) and 4 (shown in orange) present 25 amino acids 
and 60 amino acids upstream of L303, respectively, were no longer formed (Fig. 1.9D), therefore 
suggesting that even a conservative mutation in the LDEVFL motif has significant effects on the 
conformation of the C-terminal domain.  Structural changes were also observed in X306-308A 
mutation; specifically, beta-strands 1 and 6 were not seen.  Finally, the most drastic changes, as 
expected, were observed when the 13 amino acid-long LDEVFL motif was deleted.  This dele-
tion resulted in a complete loss of the beta-sheet structure (strands 1-6) of the C-terminal domain, 
without altering the structure of the N-terminal domain of DrrA (Fig. 1.9F).  These analyses not 
only confirm that the C terminus of DrrA forms an independent domain, but they also indicate 
that the conserved LDEVFL motif plays a critical role in maintaining the conformational integri-
ty of the C-terminal domain of DrrA, which would be essential for the ability of this domain to 
interact with the DrrB protein and for overall function of the complex.  This conclusion is sup-
ported by DrrA and DrrB docking analysis performed by the Rosetta dock server (28), as de-
scribed under Methods.  Results of the docking analysis (shown in Fig. S1.6) indicate that 
L303V and X306-308A point mutations in the LDEVFL motif significantly alter the orientation 
of DrrB relative to DrrA.  D304N mutation, however, showed no significant effect.  Further-
more, the distance between residue S319 in DrrA and S23 in DrrB was also significantly in-
creased in L303V (31.3 Å, Fig. S1.6C) and X306-308A (37.8 Å, S1.6D) as compared to in the 
wild type (15.5 Å, Fig. S1.6A). In D304N, as expected, the distance (14.3 Å) between these resi-
dues remained the same as in the wild type complex (Fig. S1.6B). The modeling analysis of 
DrrA is therefore consistent with the biochemical studies; both kinds of analyses highlight the 
importance of the C-terminal domain of DrrA in interaction and function of the DrrAB complex.  
Further understanding of the roles of the conserved motifs identified in this study will be ob-
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tained by genetic analysis, especially by isolation of suppressors of the mutations shown to be 
important, as well as by crystal structural analysis of the DrrA and DrrB complex.   
In summary, we propose that the interaction between the extreme C terminus of DrrA and 
the N terminus of DrrB, identified in this study, represents an initial interaction important for lo-
calization and biogenesis of the complex in the membrane.  This is shown as Confo. I in the 
working model presented in Fig. S1.7, where the N-terminal ATP-binding domains of DrrA are 
in the ‘open’ conformation, while sequences in the extreme C terminus of DrrA (319-325, in-
cluding part of CREEM) form an interface with the N-terminal tail of DrrB.  It is highly likely 
that this interaction defines the contact points in the DrrAB heterodimer isolated previously by 
use of general cross-linkers (7).  Confo. II results from binding of doxorubicin to DrrB.  In this 
state the N-terminal tail of DrrB disengages from the C terminus of DrrA.  Based on studies re-
ported earlier (23), we suggest that the N-terminal tail of DrrB is now involved in communi-
cating conformational changes to the Q-loop region (represented by residue 89) in the N termi-
nus of DrrA.  Simultaneously, the C terminus of DrrA, which is disengaged from DrrB, under-
goes homodimerization through the 33-residue region (residues 287-319, including the LDEVFL 
motif).  This is followed by binding of ATP to the N- terminal nucleotide binding domains of 
DrrA resulting in the ‘closed’ state (confo. III) produced by head-to-tail dimerization of the 
NBDs (23).  Hydrolysis of ATP returns the complex to the resting state (Confo. I). This study 
defines novel interactions between the ABC component and the transmembrane component of 
the DrrAB transporter.  It raises many interesting questions and opens new avenues for under-
standing assembly of membrane proteins. 
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Table 1.1 Effect of mutations in the LDEVFL or CREEM motif on doxorubicin resistance.   
E.coli N43 cells carrying the indicated mutation on a plasmid were streaked on M9 plates con-
taining different concentrations of doxorubicin. The growth was scored after incubation of the 
plates for 24 h at 37°C. Legend: +++, very good growth; ++, good growth; +, some growth; +/-: 
very weak growth; -: no growth. This experiment was repeated four times. Dox, doxorubicin. 
 
 
 
 
 
 
 
 
 
 
  
42 
 
 
Table 1.2 Effect of mutations in the LDEVFL or the CREEM motif on doxorubicin efflux. Dox-
orubicin efflux was measured as described under Methods.   Based on the data shown in Fig. 
S1.5, the efficiency of efflux in each LDEVFL or CREEM mutant was calculated, as described 
in Results.  The values shown are the average of the data obtained from three independent exper-
iments.  Upper  panel shows % efflux in various mutations in the LDEVFL motif.  Lower panel 
shows % efflux in mutations in the CREEM motif.  Abbreviations: 3E-3D, E(321, 322, 325)D; 
3E-3G, E(321, 322, 325)G; 4E-4Q, E(321, 322, 325, 326)Q; 5E-5G, E(321, 322, 325, 326, 
327)G. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
Fig. 1.1 Schematic representation of the conserved motifs in DrrA.  Previously identified motifs, 
located in the N-terminal domain of DrrA, include Walker A, Q-loop, signature, Walker B, and 
the switch motif (34).  The motifs identified in this study, which include LDEADQLA, LDEVFL 
and CREEM, are located in the C-terminal domain of DrrA.  Numbers indicate the location of 
specific amino acid residues.  The position of residue 319 is also marked. Panel B, effect of mu-
tations in the CREEM motif on expression of DrrA and DrrB.  Membranes were prepared as de-
scribed in Methods.  15 μg membrane protein was analyzed on 12% SDS-polyacrylamide gels, 
followed by Western blot analysis with anti-DrrA (top gel), anti-DrrB (middle gel), and anti-
SecY (bottom gel) antibodies.  A non-specific band of about 28 kDa was detected in the anti-
DrrB blot in control membranes as well as membranes containing DrrAB proteins.  Densitomet-
ric scanning of the bands in these blots was carried out as described under Methods.  Anti-SecY 
blot served as a loading control.  Panels C and D, histograms showing DrrA and DrrB expres-
sion, respectively, in various CREEM mutants.  The wild type expression level was designated 
as 1.  The data presented are averages of three independent experiments.  Error bars represent 
standard deviation.  Abbreviations used include: 3E-3D, E(321, 322, 325)D; 3E-3G, E(321, 322, 
325)G; 4E-4Q, E(321, 322, 325, 326)Q; 5E-5G, E(321, 322, 325, 326, 327)G.   
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Fig. 1.2 Disulfide cross-linkingbetween S319C in DrrA and S23C or C260 in DrrB.  Two differ-
ent cross linkers, CuPhe (copper phenanthroline) and DTME (dithio-bis-maleimidoethane), were 
used.  Anti-DrrA. and anti-DrrB antibodies were used to identify the cross-linked species.  Pan-
els A and B, lanes 1, 2: A(Y89C)B(S23C).  This strain contains one cysteine in the Q-loop at 
residue 89 of DrrA and another cysteine in the N-terminal tail of DrrB at residue 23, and it shows 
the previously characterized DrrA homodimer (23).  Lanes 3-5: A(S319C)B(S23C).  Lanes 6-8: 
A(S319C)B(C260). The plus or minus at the bottom of the gels indicates the presence or absence 
of the cross linker.  The position of the two DrrA homodimeric species, present in lanes 4 and 7, 
is marked with an oblique arrow. This experiment was repeated three times. 
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Fig. 1.3 Disulfide cross-linking between T311C, S302C, S287C, S253C, or S232C in DrrA and 
S23C in DrrB. Cysteine scan of the C terminus of DrrA (residues 232-311) was performed by 
introducing cysteines at indicated positions, followed by disulfide cross-linking assay for each of 
these cysteine substitution mutants.  Panels A and B, lanes 1, 2: A(Y89C)B(S23C); Lanes 3-5: 
A(S319C)B(S23C); Lanes 6-8: A(T311C)B(S23C); Lanes 9-11: A(S302C)B(S23C); Lanes 12-
14: A(S287C)B(S23C); Lanes 15-17: A(S253C)B(S23C); Lanes 18-20: A(S232C)B(S23C).  
This experiment was repeated three times. 
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Fig. 1.4 Sequence alignment of the C terminus of DrrA and its prokaryotic or eukaryotic homo-
logs. Panel A, sequence alignment by ClustalW of the last 30 amino acids of DrrA with C-
terminal sequences of bacterial homologs identified by NCBI BLAST search. The conserved se-
quences are termed LDEVFL motif (shown in blue) and CREEM motif (shown in red).  Panel B, 
sequence alignment of the last 29 amino acids of DrrA with 25 amino acids of the C terminus of 
NBDI (upper panel) or 26 amino acids of the C terminus of NBDII (lower panel) of ABCA2 pro-
teins from different species. Both LDEVFL and CREEM motifs are shown by this alignment. 
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Fig. 1.5 Effect of mutations in the LDEVFL motif on expression of DrrA and DrrB.  Conditions 
described in the legend to Fig. 1.1B were used. Western blot analysis was carried out with anti-
DrrA (top gel), anti-DrrB (middle gel), or anti-SecY (bottom gel) antibodies.  Anti-SecY blot 
served as a loading control. Panels B and C, histograms showing the relative amounts of DrrA 
and DrrB expression, respectively, in various LDEVFL mutants.  The wild type expression level 
was designated as 1.  The data presented are averages of three independent experiments.  Error 
bars represent standard deviation.  Abbreviations used include: X306-308A, 
V306A/F307A/L308A; X310-312A, L310A/T311A/G312A.    
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Fig. 1.6 Effect of mutations in the LDEVFL or CREEM motif on ATP binding.  UV-induced α-
32P ATP adduct formation was analyzed in membrane fractions, as described under Methods.  
The reaction was performed both in the presence (marked by +) or absence (marked by -) of 35 
µM doxorubicin.  Panels A and B, upper gels, autoradiograms showing α-32P ATP binding to 
wild type DrrAB and various LDEVFL and CREEM mutants.  Panels A and B, lower gels, 
Western blot analysis of the nitrocellulose membranes from the top gels in panelsA and B, re-
spectively, using anti-DrrA antibodies.   PanelC, a histogram showing the efficiency of ATP 
binding to wild type DrrA and mutants. The wild type efficiency was designated as 1.  The data 
presented are averages of three independent experiments.  Error bars represent standard devia-
tion.   
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Fig. 1.7 Effect of LDEVFL mutations on disulfide cross-linking between DrrA(S319C) and 
DrrB(S23C). Each LDEVFL mutation was introduced into a strain containing 
A(S319C)B(S23C) for disulfide cross-linking experiments. Panel A-i, effect of L303V mutation 
on disulfide cross-linking. lanes 1-2, A(Y89C)B(S23C); lanes 3-5, A(319C)B(S23C); lanes 6-8, 
A(S319C)B(S23C) containing the L303V mutation.  Western blot analysis was carried out with 
anti-DrrA antibody.  Panel A-ii, a histogram showing the efficiency of cross-linking in wild type 
and mutant.  The wild type efficiency was designated as 1.  The data presented are averages of 
three independent experiments.  Error bars represent standard deviation.  The column showing 
DrrA expression indicates the amount of the DrrA monomer. Panels B and D: Effect of D304N 
and X310-312A(L310A/T311A/G312A) on disulfide cross-linking, respectively.  Data are orga-
nized as in panel A. Panels C and E: Effect of X306-308A(V306A/F307A/L308A) and 
∆LDEVFL on disulfide cross-linking, respectively.   
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Fig. 1.8 Effect of mutations in the LDEVFL motif on co-purification of DrrA and DrrB.  Panel 
A, Western blot analysis using anti-DrrA and anti-DrrB antibodies.  Lanes 1-3: Sup, DrrAB pro-
teins solubilized from membrane fraction with 1% DDM; lanes 4-6: 500 mM fr. 1, first 500 mM 
imidazole elution fraction; lanes 7-9: 500 mM fr. 2, second 500 mM imidazole elution fraction.  
The intensity of bands in Western blots was determined by densitometric scanning, and co-
purification efficiencies were plotted in histograms shown in panels B and C. This experiment 
was repeated three times. Error bars in panels B and C represent standard deviation. 
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Fig. 1.9 Structure modeling of DrrA. Wild type DrrA and mutants in the LDEVFL motif of DrrA 
were modeled based on the known crystal structure of MalK  (PDB ID:2R6G) using AMMP pro-
tein structure modeling software (26), as described under Methods.  Panel A, crystal structure of 
MalK  (PDB ID:2R6G) is shown in a rectangle.  Panels B-F, predicted structures of wild type 
DrrA and mutants in the LDEVFL motif of DrrA.  Panel B, wild type DrrA; Panel C, D304N; 
Panel D, L303V; Panel E, X306-308A; Panel F, ∆ LDEVFL.  In all panels, the Walker A, Sig-
nature, and Walker B motifs in the N-terminal domain of DrrA are shown in red.  The LDEVFL 
and CREEM motifs in the C-terminal domain are shown in yellow and purple, respectively.  The 
β-strands in the C-terminal domain of DrrA are shown in different colors and are marked as 
numbers 1-6. 
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Fig. S1.1 Disulfide cross-linking between A323C or E325C in DrrA and S23C in DrrB. Two dif-
ferent cross linkers were used: CuPhe and DTME. Panel A, anti-DrrA. Panel B, anti-DrrB.  
Panels A and B, lanes 1, 2: A(Y89C)B(S23C).Lanes 3-5: A(S319C)B(S23C).  Lanes 6-8: 
A(A323C)B(S23C); Lanes 9-11: A(E325C)B(S23C). The plus or minus indicates the presence or 
absence of the cross linker.   
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Fig. S1.2 ClustalW alignment of the C terminal sequence (residues 199-315) of DrrA with the C-
terminal sequences of bacterial homologs identified by BLAST search. Sequences in 
LDEADQLA and LDEVFL motifs are highlighted.  
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Fig. S1.3 ClustalW alignment of the last 132 amino acids of DrrA with the C-terminal sequences 
of NBDI of eukaryotic homologs identified by TC-Blast search. Their homology in 
LDEADQLA and LDEVFL motifs are highlighted. 
 
 
 
 
 
 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1.4 ClustalW alignment of the last 132 amino acids of DrrA with the C-terminal sequences 
of NBDII of eukaryotic homologs identified by TC-BLAST search. Their homology in 
LDEADQLA and LDEVFL motifs are highlighted. 
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Fig. S1.5 Effect of LDEVFL or CREEM mutations on doxorubicin efflux.  E.coli LE392ΔuncIC 
cells containing the indicated plasmids were grown in TEA medium and induced with IPTG at 
OD=0.6, as described under Methods. Washed cells were de-energized with 5mM DNP and 
loaded with 10 µM doxorubicin for 11 hours. Loaded cells were washed twice, and doxorubicin 
fluorecence was measured for 100 seconds. Doxorubicin efflux by the cell suspension was then 
initiated by providing 20 mM glucose, shown with an arrow. The fluorescence was monitored for 
an additional 400 seconds. The linear region of each curve was used for calculation of the slope 
of the curve.  Panel A, effect of L303V, D304N or V306A/F307A/L308A mutation on doxoru-
bicin efflux by DrrAB.  The slopes obtained were: vector, 82; wild type DrrAB, 331; 
DrrA(L303V)DrrB, 63; DrrA(D304N)DrrB, 229; DrrA(V306A/F307A/L308A)DrrB, 84. Panel 
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B, effect of L310A/T311A/G312A mutation or ∆LDEVFL in DrrA on doxorubicin efflux by 
DrrAB. The slopes were: vector, 172; wild type DrrAB, 558; DrrA(L310A/T311A/G312A)DrrB, 
220; DrrA(∆LDEVFL)DrrB, 143. Panel C, effect of E(321, 322, 325)G, E(321, 322, 325, 326, 
327)G mutation or ∆CREEM on doxorubicin efflux by DrrAB. The slopes were: vector, 233; 
wild type DrrAB, 930; DrrA(E(321, 322, 325)G)DrrB, 832; DrrA(E(321, 322, 325, 326, 
327)G)DrrB, 507; DrrA(∆CREEM)DrrB, 429.   
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Fig. S1.6 Docking analysis of the predicted structures of DrrA and DrrB.  DrrA protein was 
modeled using AMMP modeling software and the known structure of MalK as a template.  DrrB 
protein was modeled using the Phyre modeling software (27), as described under Methods.  The 
coordinates obtained for the predicted structures of DrrA and DrrB were then used for docking 
analysis of DrrA and DrrB by Rosetta Docking server (28). Panel A, wild type DrrA and DrrB; 
Panel B, D304N and DrrB; Panel C, L303V and DrrB; Panel D, X306-308A and DrrB.  In all 
panels, DrrA is shown in green and DrrB is shown in grey. The Walker A, Signature, and Walker 
B motifs of DrrA are shown in red.  The LDEVFL and CREEM motifs in DrrA are shown in yel-
low and purple, respectively.  The β-strands in the C-terminal domain of DrrA are shown in dif-
ferent colors following the same color scheme as seen in Fig. 1.9.  The distances between S319 
(shown in magenta) in DrrA and S23 (shown in blue) in DrrB are shown in angstroms. 
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Fig. S1.7 A model showing various interactions between DrrA-DrrB and DrrA-DrrA during dif-
ferent stages of the catalytic cycle.  Both DrrA and DrrB proteins are shown as dimers.  DrrA 
protein contains two domains: an N-terminal nucleotide binding domain (abbreviated as N-ter, 
filled with blue) in the front, and a C-terminal domain (showing the CREEM motif) (abbreviated 
as C-ter) in the front.   In Conformation I, the two nucleotide binding domains in the N terminus 
of the DrrA protein are in the open state, while the extreme C terminus of DrrA forms an inter-
face with the N-terminal tail of DrrB.  It is proposed that this interaction between the extreme C 
terminus of DrrA and the N-terminal cytoplasmic tail of DrrB plays a role in assembly and bio-
genesis of the DrrAB complex.  Doxorubicin binding to DrrB produces a conformational change: 
the extreme C terminus of DrrA disengages from the N-terminal tail of DrrB, which is now in-
volved in communicating conformational changes to the Q-loop region (represented by residue 
89) in the N-terminal domain of DrrA (Confo. II). Simultaneously, the extreme C terminus of 
DrrA undergoes homodimerization.  This is followed by the ‘closed’ state, produced by the head-
to-tail dimerization of the NBDs (Confo. III). Hydrolysis of ATP returns the complex to the rest-
ing state. 
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CHAPTER 2 
A NOVEL MODULE "GATE" IS ESSENTIAL FOR STABILITY AND ENERGY 
TRANSDUCTION IN DrrAB COMPLEX 
 
2.1 Introduction 
The ATP-binding cassette (ABC) superfamily of proteins is found in organisms from all 
domains of life.  They play pivotal roles in multiple biological processes, including the import of 
nutrients and export of various toxic molecules and drugs [1].  The efflux of hydrophobic drugs 
by ABC proteins is implicated as one of the leading causes of multi-drug resistance (MDR) [2].  
ABC transporters share a common architecture consisting of two nucleotide binding domains 
(NBDs) and two transmembrane domains (TMDs). While most eukaryotic ABC proteins contain 
all four domains within the same polypeptide, the prokaryotic ABC proteins contain one NBD 
and one TMD fused together in a single polypeptide.  In some other cases, the NBD and the 
TMD are encoded on separate subunits [3].  The NBDs bind and hydrolyze ATP and provide en-
ergy for subsequent translocation of substrates through the TMDs.    
We are interested in studying the function of a drug efflux system, DrrAB, which confers 
resistance to the anticancer antibiotics doxorubicin and daunorubicin in the producer organism 
Streptomyces peucetius [4].  This system belongs to the DRA family of ABC proteins to which 
the eukaryotic proteins of the ABC sub-family A (ABCA) also belong [5].  DrrA, a peripheral 
membrane protein, plays the role of NBD and forms the catalytic subunit, while the DrrB protein 
functions as the TMD [6].  Previous studies suggested that DrrA and DrrB together form a te-
trameric complex in the membrane [7].  Furthermore, the DrrA and DrrB subunits are biochemi-
cally coupled so that proper association between these two proteins is essential for both partners 
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to achieve stability and active conformation and therefore the overall function of the transporter 
complex [7, 8].  
The N-terminal domain of DrrA contains a 198 amino acid-long ABC cassette consisting 
of all the conserved motifs that are required for ATP binding and hydrolysis.  These motifs in-
clude Walker A, Q-loop, Signature motif, Walker B, D-loop, and the Switch motif [9].  A large 
body of literature has demonstrated the formation of the characteristic head-to-tail interface be-
tween NBDs from the opposing ABC subunits within a dimer [10, 11].  In this dimeric state (also 
referred to as the closed state), the Walker A of one NBD is juxtaposed against the signature mo-
tif from the opposing NBD resulting in the formation of two ATP-binding pockets at the inter-
face.  Moreover, studies with both DrrA and MalK (ABC subunit of the maltose importer) have 
shown that the Q-loop region in these proteins facilitates formation of the closed state of the 
NBDs [9, 12].  Additional data also implied the role of Q-loop in communication of conforma-
tional changes between DrrA and DrrB during the catalytic cycle [9].  
While the sequence of the N-terminal region of the nucleotide binding domain, which 
contains the ABC cassette, is highly conserved, the C-terminal domain tends to be highly varia-
ble except in closely related ABC proteins.  Previous studies on ABC proteins have focused 
mainly on understanding the function of the ABC cassette which plays a critical role in catalysis 
and energy transduction in these proteins.  Since the C-terminal domain was believed to have 
only a scaffolding function, its role has remained largely unexplored.  Recent studies have 
shown, however, that these additional domains (when present) may be associated with special-
ized functions, thus explaining the variability in the sequence of these domains among different 
ABC proteins.  In some ABC proteins, such as ModC of the molybdate/tungstate transporter 
ModBC in Methanosarcina acetivorans and MetN of the methionine transporter MetNI from 
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Escherichia coli (E. coli), the C-terminal extension contains a binding site for the pump sub-
strate, which was shown to negatively regulate the uptake activity of the transporter through a 
trans-inhibition effect [13, 14].  The C-terminal extension of Wzt (the ABC component of the 
polysaccharide exporter Wzt-Wzm of E. coli) also binds the transport substrate; however this 
function provides substrate specificity rather than trans-inhibition [15, 16].  Additionally, the C-
terminal domain of MalK in E. coli regulates its activity at both transcriptional and post-
translational levels by binding to MalT and IIAglc, respectively [17-20].  The osmoregulatory 
transporter OpuA from Lactococcus lactis senses the ionic strength and osmotic stress through 
its C-terminal extension which possibly forms an alkali ion binding site [21].  The crystal struc-
tures of several ABC proteins have become available in recent years.  These structures have re-
vealed a common β-sheet fold in their C-terminal domains despite the diversity present in their 
amino acid sequences, indicating that this structure may be critical for the function of this do-
main [13-15].   
We previously identified three novel motifs in the C-terminal domain (amino acids 199-
330) of DrrA [22].  The function of two motifs, LDEVFL (302-SLDEVFLALTGH-313, referred 
to as DEF in this chapter) and CREEM (321-EEAAEEEKVA-330) present in the extreme C ter-
minus of DrrA, was previously characterized in this laboratory [22].  Not only were these motifs 
shown to be critical for function of the DrrAB complex, but the CREEM motif, together with its 
upstream region up to Ser319, was also shown to be directly involved in interaction with the N-
terminal cytoplasmic tail of DrrB.  The DEF motif was found to regulate this interaction and 
therefore possibly the assembly and function of the DrrAB complex.  The DEF motif was also 
found to participate in homodimerization of DrrA, which may be an important prerequisite for 
DrrA-DrrB interaction.  The 3-dimentional model of DrrA, which was generated using MalK as 
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a template, showed that the C-terminal domain of DrrA also contains a β-sheet fold structure 
similar to the one seen in other ABC proteins.  Interestingly, the DEF and the CREEM motifs 
were also found to be conserved among a number of prokaryotic and eukaryotic homologs be-
longing to the DRA family of ABC proteins, most notable among these being the mammalian 
ABCA proteins involved in lipid export.   
The present study focuses on the third conserved domain, Glycine-loop And Transducer 
Element (GATE, referred to as LDEADQLA in previous chapter), whose function remains com-
pletely unknown.  This domain contains 33 residues and is located immediately downstream of 
the Switch motif of the NBD.  The GATE domain is conserved not only among close homologs 
of the DRA family, but is also found in ABC proteins from other families.  We report here the 
presence of three highly conserved glycines, including G215, G221 and G231, within the GATE 
domain, which are critical for the structural integrity and function of the DrrAB complex.  We 
found that G215 contacts residues in the Walker A and surrounding area.  Therefore it may be 
indirectly involved in ATP binding and/or catalysis.  This residue together with G221 is also 
shown to be essential for the stability of the DrrAB complex.  G231 and nearby residues, includ-
ing L226 as well as K227, are functionally important and, based on our biochemical data and 
structural analysis, may constitute a conformational relay between the NBD and TMD during the 
overall translocation process. 
2.2 Material and methods 
Bacterial, plasmids, and antibodies- The bacterial strains used in this study were E. coli TG1, 
N43, LE392ΔuncIC, CC118, and XL1-Blue.  The plasmids used included pDx101 (drrAB in 
pSU2718), LA330 (drrA::lacZ fusion in pMLB1069), LAB15 (drrA and the first 45 base pairs of 
drrB::lacZ fusion in pMLB1069), LAB283 (drrA-drrB::lacZ fusion in pMLB1069).  Various 
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substitutions were created in drrA and drrB genes in the above plasmids.  For Western blot anal-
ysis, rabbit polyclonal antibodies against DrrA and DrrB proteins were used [6].  
Growth conditions and Media- For site-directed mutagenesis, XL1-Blue cells were grown at 
37°C in NYZ+ broth [pH 7.5, 1% (w/v) casein hydrolysate, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl] supplemented with 12.5 mM MgCl2, 12.5 mM MgSO4 and 0.4% (w/v) glucose (La Jolla, 
CA).  For doxorubicin efflux experiments, cells were grown in TEA medium [50 mM triethano-
lamine HCl (pH 6.9), 15 mM KCl, 10 mM(NH4)2SO4, 1 mM MgSO4] supplemented with 0.5 % 
(w/v) glycerol, 2.5 µg/ml thiamine, 0.5 % (w/v)  peptone, and 0.15 % (w/v) succinate at 37°C. 
LB medium was used for all other cell growth unless mentioned otherwise.  Chloramphenicol 
was added to 20 μg/ml, and ampicilin was added to 75 μg/ml, where needed. 
Site-directed mutagenesis- Both highly and less conservative mutations were introduced into the 
GATE domain of DrrA by using the QuickChange multi-site-directed mutagenesis kit (Strata-
gene).  For this technique, complementary primers were designed to incorporate the mutation at 
the desired position.  pDx101, LA330, LAB15 and LAB283 were used as templates.  Primers 
were designed as described before [23].  In GATE domain, the highly conservative mutations 
included E201D, L205V, G215A, G221A, L226V, K227R and G231A.  In addition, E201Q, 
G215S, G215P, G221S, G231S were generated as the less conservative mutations.  Cysteine 
substitutions were constructed in different motifs using the cysteine-less drrAB as the template. 
The cysteine-less drrAB was obtained by introducing a mutation C260S in drrB in pDX101.  The 
cysteine substitutions included V211C (GATE domain), T222C (GATE domain), S319C (DEF 
motif) and S23C (N-terminal tail of DrrB).  
Measurement of β-galactosidase activity- The activity of the fusion proteins was determined by 
the methods published earlier [23].  
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Doxorubicin resistance assay of GATE domain mutants- The indicated plasmids were trans-
formed into E.coli N43 cells.  Note that this strain is doxorubicin sensitive.  A single colony was 
inoculated into 5 ml of LB medium supplemented with 20 μg/ml chloramphenicol and incubated 
at 37 °C for 8h.  1 μl of the cell suspension was streaked onto M9 plates with a top layer contain-
ing 0, 4, 6, 8 or 10μg/ml doxorubicin.  Since doxorubicin is light sensitive, the plates were cov-
ered with foil and incubated at 37 °C for 24 h.    
Doxorubicin efflux assay of GATE domain mutants- The efflux assay was carried out as de-
scribed earlier [22].  Briefly, E. coli LE392ΔuncIC cells were transformed with the indicated 
plasmids.  Cells were grown in supplemented TEA medium to mid-log phase (optical density 
600 nm = 0.6) and induced with 0.1 mM isopropyl 1-thio-β-D-galactopyranoside (IPTG) for 1 
hour, harvested and washed with TEA twice and resuspended in 1 ml of TEA.  10 l of the cell 
suspension from above was incubated in 3 ml of TEA medium containing 10 µM doxorubicin 
and 5 mM 2, 4-dinitrophenol (DNP) for 11 hours at 37°C.  The loaded cells were washed twice 
with 0.1 M MOPS buffer, pH 7.0, containing 2.0 mM MgSO4 and resuspended in 3 ml of MOPS 
buffer.  The fluorescence spectra were recorded on an Alphascan-2 spectrofluorometer (Photon 
Technology International, London, Ontario, Canada).  The excitation wavelength for doxorubicin 
was 480 nm and emission was monitored at 590 nm.  The excitation and emission slit widths 
were set at 0.75 and time based script was run.  After an initial recording of fluorescence for 100 
seconds at 37°C, energy was provided in the form of 20 mM glucose and recording was contin-
ued for an additional 400 s. 
The rate of doxorubicin efflux was determined by calculating the slope of the linear portion of 
each efflux curve.  The final slope of each mutant was obtained by subtracting the slope of the 
control (E. coli cells containing the empty vector) from the slope of each efflux curve.  The dox-
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orubicin efflux efficiency for each GATE domain mutant was then calculated as the percentage 
of the mutant slope/wild type slope.   
Effect of GATE domain mutants on ATP binding assay- In order to study the nucleotide bind-
ing ability of various GATE domain mutants, pDx101 bearing the indicated mutations were 
transformed into E. coli TG1 cells, which were grown at 37°C to mid-log phase and induced 
with 0.1 mM IPTG for an additional 3h at the same temperature.  The membrane fraction was 
prepared as follows.  Cells were spun down, resuspended in buffer A [25 mM Tris-Cl (pH7.5), 
20% glycerol, 2 mM EDTA (pH8.0), 1 mM DTT] and lysed by French press at 16,000 p.s.i.. 
Cells were centrifuged at 10,000 g at 4°C for 30 min followed by centrifugation of the superna-
tant at 100,000 g at 4°C for 1h.  The obtained pellet was washed twice and finally resuspended in 
buffer A.  The photolabeling of DrrA with [α-32P] ATP was carried out in a 100 µl reaction sys-
tem containing buffer A, 0.1 mg of membrane protein, 10 µM ATP (pH7.5), 10 µCi of [α-
32P]ATP, 35 µM doxorubicin and 5mM MgCl2.  The reaction was exposed to UV light at 254 nm 
on ice for 30 min, followed by protein precipitation by 10% ice-cold TCA on ice for 30 min.  
Protein was recovered by centrifugation at 14,000 g for 15 min and the pellet was resuspended 
into 20 µl of 4x Laemmli sample buffer and 5 µl 1M unbuffered Tris.  The samples were re-
solved by polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane.  The 
membrane was air-dried and exposed to x-ray film at -70°C overnight, followed by autoradiog-
raphy.  The same blot was then examined by Western blot using anti-DrrA antibody. 
Effect of GATE domain mutants on disulfide cross-linking- A 100 μl reaction volume contain-
ing 250 μg of membrane protein in 0.1M phosphate buffer pH 7.4 (0.1M of Na2HPO4 and 0.1M 
NaH2PO4) was treated with thio-specific reagents including copper phenanthroline (CuPhe; 3 
mM CuSO4, 9 mM 1, 10-phenanthroline) or 1 mM dithiobismaleimidoethane (DTME, Pierce).  
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The cross-linking reaction was carried out at room temperature for 30 min and stopped by adding 
4x Laemmli sample buffer.  A 25 μl portion (50 μg of membrane protein) of the reaction mixture 
was then analyzed by 10% SDS-polyacrylamide gel, followed by Western blot analysis using 
anti-DrrA or anti-DrrB antibodies. 
Modeling analysis of GATE domain mutants- AMMP protein structure modeling software 
([24],   http://asterix.cs.gsu.edu/ammp.html) was used for homology modeling of DrrA mutants 
as stated previously [22]. PyMOL Molecular Graphics System ([25], http://www.pymol.org/) 
was used to measure the atomic distances, view and present protein structures. 
2.3 Results 
Identification of the GATE domain in DrrA and other ABC proteins- The N-terminal 198 ami-
no acid nucleotide binding domain of DrrA contains all the conserved motifs involved in ATP 
binding and hydrolysis [9].  Recent studies from this laboratory identified three novel motifs 
(CREEM, DEF, and GATE) in the C-terminal 132 amino acid domain of DrrA (residues 199-
330).  Two of these motifs, CREEM and DEF, present at the extreme C-terminus, were charac-
terized previously [22].  The GATE domain, which is present 104 amino acids upstream of DEF 
in a region immediately following the Switch motif of the NBD, is the topic of the present study.  
This domain was found to be highly conserved among close DrrA homologs belonging to the 
DRA family of ABC proteins (Fig. 2.1A).  A multiple sequence alignment of DrrA with ABC 
transporters outside the DRA family, including MalK, ModC, BtuD, P-glycoprotein (Pgp), Cyst-
ic fibrosis transmembrane conductance regulator (CFTR), MsbA, and Sav1866, showed that the 
GATE domain is also conserved in ABC proteins from other families, albeit with varying de-
grees of similarity (Fig. 2.1B).  The alignments shown in Figs. 2.1A and 2.1B point out that the 
homology in this region extends across the length of the 33 residue GATE domain.  Of these res-
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idues, E201, G215, G221, L226, K227, and G231 are the most conserved among DRA family 
members.  Among distant homologs, A206, G215 and G221 are the most highly conserved resi-
dues.  These observations indicate that G215 and G221 must be critical for the general function 
of this domain across different ABC families, while the residues conserved only among members 
of the DRA family may play a more specific role.  The crystal structures of several ABC proteins 
(including MalK, ModC, BtuD, Pgp, CFTR, MsbA and Sav1866) are available [11, 13, 26-29], 
however no member of the DRA family has been crystallized so far.  A comparison of the differ-
ent crystal structures suggested a high structural conservation in the region of the GATE domain.  
The structures of MalK, CFTR and Sav1866 shown in Figs. 2.2B-D suggest that this region con-
tains two β-sheets sandwiched by an α-helix on either side.  A homology model of DrrA, based 
on the MalK structure, was developed previously [22], which also showed a very similar fold in 
the region of the GATE domain (Fig. 2.2A).  The highly conserved residue G215 was found to 
be present in the turn region between the two β-sheets in each structure.  This loop is termed the 
‘Gly-loop’ (G-loop) in this article.  The locations of G215 along with several other conserved 
residues are marked in Fig. 2.2A and color-coded in Figs. 2.2B-D. 
Conserved glycines (G215 and G221) in the GATE domain are critical for stability of the 
DrrAB complex- To determine if the GATE domain is essential for function of the DrrAB com-
plex, site-directed mutagenesis of conserved residues in this domain was carried out resulting in 
several mutants, including E201D, E201Q, L205V, G215A, G215S, G215P, G221A, G221S, 
L226V, K227R, G231A and G231S.  The Western blot analysis of the membrane fractions gen-
erated from the above mutants showed that the expression of DrrA and DrrB was affected to var-
ying degrees in different mutants (Fig. 2.3).  For example, mutants E201D, G215A/S/P and 
G221A/S showed moderate to severe reduction in the levels of DrrA and DrrB expression as 
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compared to the wild-type, however L205V, L226V, K227R, G231A, and G231S produced no 
significant effect on expression.  Interestingly, when E201 was substituted with glutamine in 
E201Q mutant, the stable expression of both DrrA and DrrB was almost completely prevented, 
indicating that the negative charge of E201 may be essential for the stability of DrrAB.   
Notably, mutagenesis of the highly conserved residue G215 to G215A, G215S, or G215P 
completely abolished the expression of DrrB (Fig. 2.3A, lanes 6-8 and Fig. 2.3B).  To determine 
whether the expression was affected at the translational or post-translational level, G215A muta-
tion was introduced into a translational fusion LA330 (constructed previously in this laboratory) 
created between the extreme C terminus of DrrA (residue 330) and the β-galactosidase gene.  
The β-galactosidase activity of this fusion served as a measure of the translation level of the drrA 
gene.  G231A mutation in DrrA, which showed normal DrrA and DrrB expression on Western 
blot analysis (Fig. 2.3A, lane 13), was used as a control.  The data in Fig. 2.4A show that the 
translation of DrrA containing the G215A mutation is about 80% as compared to that of wild 
type DrrA, while the translation of DrrA containing the G231A mutation was unaffected.  Simi-
lar experiments were also performed with two other translational fusions, LAB15 (in which β-
galactosidase is fused to the first 15 amino acids of DrrB) and LAB283 (in which β-galactosidase 
is fused to the last amino acid, residue 283, of DrrB).  The β-galactosidase activity of these fu-
sions served as a measure of the translation levels of the coupled drrAB genes.  In both the 
LAB15 and LAB283 backgrounds, the β-galactosidase activity of the strains containing G215A 
and G231A was comparable to the wild type (Figs. 2.4B and 2.4C), indicating that translation of 
the drrAB genes was not affected by the G215A mutation.  Therefore, an additional post-
translational effect must be responsible for the observed drastic effect on DrrA and DrrB expres-
sion in this mutant.  This additional effect may result from the inability of the mutated DrrA 
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(bearing G215A) to interact with DrrB or from dissociation of DrrA and DrrB due to structural 
changes (as discussed later).  Based on these analyses, we conclude that the G215 residue plays 
an indispensible role in maintaining the stability and/or proper folding of DrrAB.  Furthermore, 
data in Fig. 2.3 show that the G221A and G221S mutations also significantly affect DrrAB ex-
pression though not to the same extent as the G215 mutations.  Since either of these glycines 
could not be changed to Ala or Ser without affecting expression levels in a significant manner, 
we conclude that both G215 and G221 are critical for maintaining stability of DrrA and DrrB.  
The third conserved glycine, G231, on the other hand could be mutated to Ala or Ser without af-
fecting expression or stability, indicating that this residue is not involved in stability but may 
play a specific role in function, as shown later. 
Several other conserved residues (E201, G221, L226, K227, and G231) in the GATE domain 
are also critical for the function of the DrrAB complex- To determine if residues in the GATE 
domain are critical for function, several functional assays, including doxorubicin resistance, dox-
orubicin efflux and ATP binding, were performed.  Doxorubicin resistance analysis showed var-
ying degrees of sensitivity to doxorubicin resulting from different mutations (Table 2.1).  To 
study the effect of mutations on drug transport, de-energized E. coli LE392ΔuncIC cells, contain-
ing the mutant DrrA and wild type DrrB, were loaded with doxorubicin, as described under ‘Ma-
terial and methods’.  The DrrAB-mediated doxorubicin efflux in preloaded cells was then initiat-
ed by addition of glucose.  While fluorescence of doxorubicin is quenched on its binding to DNA 
inside the cells, its efflux on addition of energy is seen as an increase in its fluorescence (Figs. 
S2.1- S2.4).  The rate of doxorubicin efflux was determined by calculating the slope of the linear 
portion of each efflux curve shown in Figs. S2.1- S2.4.  The final slope of each mutant was ob-
tained by subtracting the slope of the control (E. coli cells containing the empty vector) from the 
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slope of each efflux curve.  The doxorubicin efflux efficiency for each GATE domain mutant 
was then calculated as the percentage of the mutant slope/wild type slope.  The data shown in 
Fig. 2.5 (which represent averages of three independent experiments) suggest that several muta-
tions, including E201D, E201Q, G215A/S/P, G221A/S, L226V, K227R, and G231S, produced a 
severe reduction in the efficiency of doxorubicin efflux.  Of these, E201Q and G215A/S/P con-
tained undetectable levels of DrrB (Fig. 2.3), therefore the actual effect of these mutations on 
doxorubicin efflux cannot be easily assessed.  E201D and G221A/S mutations show moderate 
(31%-52% of Wild Type) DrrAB expression but are severely affected in doxorubicin efflux (5%-
14% of wild type), implying that these residues may be important for the function of the com-
plex.  However, the most clear-cut phenotypes were obtained with the L226V, K227R and 
G231S mutations, which show normal DrrAB expression but a drastic reduction in doxorubicin 
efflux.  Of special note is the difference observed between G231A and G231S mutants.  While 
both show normal DrrAB expression, G231S shows less than 1% doxorubicin “efflux efficiency” 
but G231A still exhibits about 50% efflux.  Since the serine substitution is expected to make the 
structure of this region more rigid than alanine, these results imply that the residue G231 might 
be critical for flexibility of this region.  However, the flexibility imparted by G231 seems to be 
more important for function of the complex instead of protein expression or stability.  Overall, 
the efflux data were also found to be largely consistent with the results of the doxorubicin re-
sistance assay shown in Table 2.1, except that L226V mutant showed moderate level of re-
sistance but very low efflux.  The reason for this discrepancy is not clear; however, the efflux 
data are much more quantitative than the resistance data, therefore we believe that the low efflux 
efficiency accurately reflects the status of this mutant. In summary, the results of these analyses 
allow us to conclude that the conserved residues E201, G221, L226, K227, and G231 are critical 
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for the doxorubicin efflux function of the DrrAB transporter.  Moreover, the three conserved 
glycines, G215, G221 and G231, are important for providing structural integrity and flexibility to 
this region.  Of these, G215 and G221 are critical for stability, while G231 plays a crucial role in 
function.  
Role of the conserved residues of the GATE domain in ATP binding-  To determine if the de-
fect in the doxorubicin resistance and efflux function of certain GATE mutants is due to an effect 
on ATP-binding, UV-induced [α-32P] ATP binding to DrrA was analyzed (Fig. 2.6).  The ATP-
binding ability of each mutant was normalized by calculating the ratio of ATP bound (in the 
presence of doxorubicin)/the amount of DrrA in each sample.  The efficiency of ATP binding 
was then calculated as the ratio of ATP binding to mutant/wild type for each mutant, and the av-
erages of the data were plotted in Fig. 2.6B.  Even though many mutants were tested for their 
effect on ATP binding, of special interest were the mutants that showed normal or moderate ex-
pression of DrrA and DrrB, but drastically diminished doxorubicin efflux capability, for example 
E201D, G221A, G221S, L226V, K227R, and G231S (Figs. 2.3 and 2.5).  Of these, the K227R 
mutant, surprisingly, retained full efficiency of ATP binding (Fig. 2.6).  Since the efflux function 
of K227R is significantly compromised, normal ATP binding to this mutant indicates that its 
function may be compromised in a later stage of catalysis,  such as  coupling between ATP bind-
ing and drug translocation.  All other mutants in the category mentioned above retained about 
35-57% ATP binding efficiency, but rather poor efflux, therefore it is likely that they are also 
defective in catalysis (as with K227R).  Previous studies have shown that DrrA fails to bind ATP 
in the absence of DrrB [7]. Therefore, G215 mutations were not tested for ATP binding as no 
DrrB protein was detected in these mutants.  Overall, based on the analyses described above, we 
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conclude that several highly conserved residues in the GATE domain are critical for the catalytic 
and the doxorubicin efflux functions of the DrrAB complex.  
The GATE domain does not show direct interaction with the N-terminus of DrrB- Previous 
studies from this laboratory showed that DrrA interacts mainly with the N-terminal cytoplasmic 
tail region (residue 1-53) of DrrB [23].  In chapter 1, we showed that in addition to interacting 
with the Q-loop region of DrrA, the N-terminus of DrrB forms a dimer interface with the con-
served motif CREEM in the extreme C terminus of DrrA [22].  To determine if the GATE do-
main is also involved in a similar interaction with DrrB, two separate cysteine substitutions, 
V211C and T222C, were created in a strain containing S23C in the N terminus of DrrB.  Homo-
bifunctional cross-linkers CuPhe and DTME were used to treat the membranes generated from 
the above strains.  As shown previously (and in lanes 3-5 in Fig. 2.7), when a cysteine is intro-
duced in position 319 which lies immediately upstream of DEF, a strong interaction between 
S319C in DrrA and S23C in DrrB can be seen with both cross linkers, indicating close proximity 
between S319 and S23 residues and association between these two regions.  However, no DrrAB 
dimer was seen in the membranes containing V211C(DrrA)/S23C(DrrB) or 
T222C(DrrA)/S23C(DrrB) (Lanes 6-11, Figs. 2.7A and 2.7B), which suggests that the GATE 
domain residues do not interact directly with DrrB. 
Insights from the structural analysis of the GATE domain in MalK and DrrA- Since the resi-
dues of the GATE domain are conserved in many ABC proteins, we performed structural analy-
sis using the crystals of the bacterial ABC protein MalK.  The crystal structure of DrrA or the 
DrrAB complex is so far not available, however the homology model of DrrA, which was pub-
lished previously [22], was used to obtain additional insights. 
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Interactions around residue G210 in MalK - The ATP-bound (closed state, PDB access 
ID: 1Q12) and the ATP-free(open state, PDB access ID: 1Q1E) forms of MalK (E. coli), which 
were published together previously [11], were used for analysis of the conserved residues in the 
GATE domain.  Based on the sequence alignment shown in Fig. 2.1B, the conserved residue 
G215 in DrrA is equivalent to G210 in MalK.  Using the closed state 1Q12, our structural analy-
sis showed that the residue G210 lies in close proximity to the Walker A motif within the same 
chain of MalK (Fig. 2.8A, shown in cyan color) such that a direct hydrogen bond of N-H...O 
type with a distance of 2.9 Å from NH group of G210 to carboxylate oxygen of C40 (located 
within Walker A) was found (Fig. 2.8A).  Notably, the CA of G210 forms another two unconven-
tional hydrogen bonds of the C-H...O type with C40 and V18 at the distance of 3.4 and 3.3 Å, 
respectively (Fig. 2.8A).  It was demonstrated previously that both C40 and V18 in MalK make 
direct contacts with ATP in the head - to - tail ATP binding interface of the NBD dimer [11].  
For example, C40 forms a hydrogen bond with the β phosphate of ATP, whereas V18 stabilizes 
ATP by van der Waal interaction with the ribose of ATP.  Similar atom bonding patterns be-
tween G210 and the Walker A residues were also observed in the open state of MalK (1Q1E, 
shown in slate) though minor variations in distances between atoms were seen (Fig. 2.8A).  This 
observation suggests that the interactions between these residues are maintained stably both in 
the open and the closed states and probably during the whole ATP catalysis process.  No signifi-
cant interactions were found between other conserved residues (such as those corresponding to 
G221, L226, K227, G231 in DrrA) in the GATE domain and the Walker A or other regions of 
MalK.    
Superimposition of the open and closed states of MalK - To get a clearer idea of the dynamics of 
G210 and the Walker A residues during catalysis, 1Q1E and 1Q12 structures were superim-
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posed.  As seen in Fig. 2.8B, a change from the open state (shown in slate) to the closed state 
(shown in cyan) results in a movement of C40 (residue shown in white color) by 5.4 Å.  A com-
parable movement of G210 (5.0 Å, residue shown in yellow) and V18 (6.9 Å, not shown) was 
also observed.  This pattern of movement is not limited to these three residues, but is also seen in 
other important motifs of the NBD, including the complete Walker A loop, the Signature, Walk-
er B, the G-loop region (consisting of A209 and G210) and the two surrounding β-sheets.  By 
comparison, other regions, such as the α-helix immediately after the second β-sheet in the GATE 
domain, exhibited no obvious movement.  These observations imply that ATP binding produces 
general conformational changes in the regions that are involved in ATP-binding, and these re-
gions may include not only the conventional ATP binding motifs, but also the G-loop in the 
GATE domain.  In summary, G210 forms three hydrogen bonds with residues C40 and V18.  
These interactions were maintained both in the absence and presence of ATP.  Furthermore, su-
perimposition of the ATP bound and ATP-free states of MalK points out that the G-loop moves 
together with Walker A and other important ATP binding motifs during ATP catalysis.   
Insights from the homology model of DrrA and the GATE domain mutants - To get a better un-
derstanding of the function of the GATE domain in DrrA, the previously generated 3-
dimensional homology model of wild type DrrA was analyzed.  The homology models of several 
mutants, including G215A and K227R, were also generated in the present study using the 
AMMP software [24].  In the wild type DrrA structure, G215 (which corresponds to G210 in 
MalK) was once again found to lie in close proximity to A45 (which corresponds to C40 in 
MalK, [9]) and A23 (corresponding to V18 in MalK) (Fig. 2.8C).  However, the distance from 
the NH group of G215 to carboxylate oxygen of A45 was found to be 3.7 Å, which is longer than 
required for hydrogen bond formation.  Additionally, the distance from the CA of G215 to the 
82 
 
carboxylate oxygen of A45 and A23 were 4.3 and 3.1 Å, respectively.  Thus, an unconventional 
hydrogen bond C-H...O is formed between G215 and A23 (similar to the bond between G210 
and V18 in MalK), however, the other two bonds seen in MalK were not identified in the DrrA 
model.  Even though the homology model is not expected to be as accurate as the crystal struc-
ture,   modeling analysis allowed a comparison of the structure of wild type DrrA with those of 
various mutants, thus providing important information in this respect.  For example, analysis of 
the G215A mutant showed dramatic changes in interactions around 215 so that the three distanc-
es mentioned above were changed to 2.8 (N215-O45), 3.2 (CA215-O45), and 4.5 Å (CA215-O23), re-
spectively, resulting in a change of between 0.9-1.4 Å in each case (Fig. 2.8D).  Analysis of an-
other important residue K227also provided interesting insights.  It was found that K227 forms a 
C-H...O bond at a distance of 3.5 Å with Ser319 located between the DEF and CREEM motifs in 
the extreme C terminus of DrrA (Fig. 2.8E).  Strikingly, this distance is increased to 12.8 Å in 
the K227R mutant (Fig. 2.8F).  Since S319 is involved in a direct interaction with the N-terminus 
of DrrB [22], its interaction with K227 could be potentially very important in the function of the 
GATE domain.  The significance of these findings is discussed later. 
2.4 Discussion 
This  study characterizes a recently identified domain, termed GATE, in the ABC protein 
DrrA [22].  The GATE domain is present in the middle of the DrrA protein with the highly con-
served ABC cassette in the N-terminal domain and the conserved DEF and CREEM motifs in the 
C-terminal domain.  Our studies indicate that the GATE domain is conserved in both the close as 
well as the distant homologs of DrrA (Fig. 2.1), however no biochemical or functional character-
ization of this domain of the ABC protein family has been reported thus far. 
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The GATE domain of DrrA is 33 amino acids long and contains three highly conserved 
glycines, G215, G221, and G231.  . Here we show that G215 and G221 are mainly involved in 
maintaining the stability of DrrAB complex, whereas G231 may play an important role in func-
tion.  Strikingly, mutagenesis of G215 to Ala, Ser, or Pro completely prevented stable expression 
of DrrB, while mutation of G221 to either Ala or Ser reduced DrrB expression to about 50%.  
Furthermore, doxorubicin efflux in G221A and G231S mutants was drastically reduced, which 
indicates that in addition to its role in stability, G221 may also be critical for function of the 
complex.   
β-galactosidase fusion analysis showed that the translation of DrrA and DrrB is unaffect-
ed by the G215A mutation in DrrA.  Therefore, the effect of G215 mutations on protein expres-
sion seems to be post-translational in nature, possibly resulting from the inability of DrrA (con-
taining a mutated G215 residue) to interact with DrrB.  It was previously established in this la-
boratory that the stable expression of DrrB is dependent on its interaction with DrrA expressed 
either in cis or trans[7].  From the data reported in this chapter, it is evident that the proper con-
formation provided by the glycines in the GATE domain is an important element for stability of 
the complex, however the molecular mechanism by which G215 and G221 facilitate DrrAB in-
teraction remains an open question.  Whether these glycines play a direct or an indirect role in 
stability of DrrAB remains to be elucidated.  Atomic analysis of the tertiary structure of MalK 
and the homology model of DrrA showed that the G215 residue forms close contacts with resi-
dues in the Walker A motif in the NBD of these proteins.  The possible implication of this find-
ing in maintaining stability is discussed later.   
Interestingly, mutations of the third glycine G231 did not produce a negative effect on the 
stability of DrrAB, however a striking difference in the function of the G231A and G231S alleles 
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was observed.  While G231A exhibited normal levels of ATP binding and about 50% doxorubi-
cin efflux efficiency, the G231S mutation reduced ATP binding to about 35% and efflux effi-
ciency to about 1%.  Since the serine substitution is expected to make the structure of this region 
more rigid than alanine, the more drastic effect of the G231S mutation would suggest that the 
flexibility conferred by G231 is critical for function.  Glycines are frequently found in ‘turns’ 
and ‘bends’ in many proteins, where they are known to confer structural flexibility important for 
function [30].  The lack of a side chain in a glycine residue allows a domain having glycines the 
mobility that is necessary for acquiring variability of angles and rotational flexibility.  A classical 
example is the hinge region of the human immunoglobulin G protein (IgG).  The mobility of an-
tibody arms in IgG, which is fundamentally important for epitope-IgG interaction, is dependent 
on the presence of glycine in the hinge region [31].  Further, studies on the DNA-binding pro-
teins such as the lactose repressor (E.coli) and hemagglutinin/protease regulatory protein (Vibrio 
Cholerae) suggest that Glycines in the hinge region of these proteins are essential for conferring 
favorable flexibility that is needed for optimal interaction between the protein and target DNA 
sequences [32, 33].  Our studies, therefore, show for the first time that the conserved glycines in 
this novel domain of DrrA are important for function of ABC proteins. 
In addition to the three conserved glycines, other highly conserved residues in the GATE 
domain, including E201, L226, and K227, were also found to be critical for the doxorubicin ef-
flux function of the DrrAB transporter.  Of special note is the K227R mutation which resulted in 
significant reduction of doxorubicin efflux efficiency without affecting ATP binding, thus indi-
cating that defective transport in K227R likely results from a defect in a later step in the catalytic 
process, which is discussed later.   
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Overall the studies reported in this article suggest that the GATE domain is an interesting 
and a very important motif for the function of ABC transporters.  To gain further insights into its 
mechanism, we analyzed the crystal structure of the MalK protein since no member of the DRA 
family has thus far been crystallized.  The analysis of the MalK structure at the atomic level re-
vealed that residue G210 (G215 in DrrA), present in the G-loop (Fig. 2.2), forms three hydrogen 
bonds with residues C40 and V18 in the Walker A motif (Fig. 2.8A), which are known to interact 
directly with ATP bound at the interface of the MalK dimeric structure [11].   Since these hydro-
gen bond interactions between G210 and the Walker A residues were seen both in the open and 
the closed states of the MalK dimer, they likely play a critical role in fixing C40 and V18 in a 
favorable orientation for ATP-binding.  This observation may explain why the G215A mutation 
in DrrA produces such a drastic effect on the stability of the DrrAB protein complex.  Substitu-
tion of this Gly with Ala likely abolishes these hydrogen bonds therefore resulting in displace-
ment of these residues and disturbing the structural integrity of the ATP-binding pocket and sta-
bility of DrrA.  As a consequence, DrrB is expected to be destabilized and degraded since inter-
action with DrrA is essential for maintaining the stability of DrrB [7].  Therefore, the proper 
spacing between residue 215 and the residues in Walker A motif may only be accomplished by 
glycine due to its minimal side chain, which could be essential for integrity of the ATP-binding 
pocket and, therefore, the stability of the DrrAB complex.  
Interestingly, the superimposition of the open and the closed states of MalK showed a 
comparable and parallel movement of G210 with C40 and V18, suggesting that the G-loop 
moves together with Walker A and other important ATP binding motifs during catalysis.  These 
findings once again suggest that the constant hydrogen bonding between C40 and V18 in Walker 
A and G210 in G-loop is essential for producing a favorable conformation required for success-
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ful ATP binding.  It is very interesting to note that the consensus Walker A sequence 
(GxxGxGKS/T, where x represents any amino acid) also contains three highly conserved glycine 
residues, which make hydrogen bonds with the phosphates of ATP [11].  Mutations of these gly-
cine residues in the Walker A of DrrA were previously shown to affect the ATP-binding ability 
of DrrA as well as the stability of DrrA and DrrB.  Therefore, it may be reasonable to propose 
that along with the three conserved glycines in the Walker A loop, G210 (G215 in DrrA) may 
also be important for maintaining or constituting the ATP binding pocket. 
Analysis of the homology model of DrrA generally supported the findings from the MalK 
crystal structure in terms of the proximity and interactions between G215 and residues in the 
Walker A motif, though two of the three hydrogen bonds seen in the crystal structure were not 
identified in the modeled DrrA structure.  This is not surprising since accurate and reliable meas-
urements of atomic distances are not possible with a homology model.  Nevertheless, in the ab-
sence of any crystal structures of the mutants, modeling analyses allow for comparisons of the 
structures of the wild type protein with the mutants and can provide important insights.  Accord-
ingly, we compared the structure of the wild type DrrA with the G215A as well as the K227R 
mutant.  Interestingly, G215A showed dramatic changes in interactions of G215 with Walker A 
residues, suggesting that the space around 215 can only accommodate Gly but not Ala.  This 
substitution forced A215 to move towards A45 (C40 in MalK) and away from A23 (V18 in 
MalK), which may exert a negative effect on structural integrity of the ATP binding pocket, as 
mentioned earlier.  Therefore, based on the structural analysis of MalK and DrrA, we propose 
that the specific effect of G215 mutations on stability of the complex (especially DrrB) is not due 
to a direct interaction of the GATE domain with DrrB but occurs indirectly through the effect of 
these mutations on the integrity of the ATP-binding pocket.  This conclusion is also supported by 
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the cross-linking data shown in Fig. 2.7, where no evidence of disulfide bond formation was seen 
between V211C or T222C in the GATE domain and S23C in the N-terminus of DrrB.  In con-
trast to V211C or T222C, cysteine substitutions in the extreme C-terminus of DrrA, such as 
S319C, A323C or E325C, show strong disulfide bond formation with S23C [22], indicating di-
rect interaction between these domains.   
Additional important insights were obtained from a comparison of wild type DrrA with 
the K227R mutant.    The drastically affected doxorubicin efflux of K227R indicates that the 
K227 residue is important for the function of the DrrAB transporter.  Interestingly, our structural 
analysis showed that the K227 residue makes a hydrogen bond (of the C-H…O type) with S319 
at a distance of 3.5Å, which is increased to 12.8 Å in the K227R mutant. Since the C terminus of 
DrrA (which includes residue S319) makes direct contacts with the N terminus of DrrB, as 
shown in Chapter 1 [22],  it is possible that K227 plays a key role in transmitting conformational 
changes derived from ATP binding to the N-terminus of DrrB through its interaction with S319.  
Given the fact that the K227R mutant is functionally defective (Fig. 2.5) but shows normal ATP-
binding (Fig. 2.6), it is reasonable to propose that ATP catalysis is uncoupled from substrate 
translocation in this mutant, possibly due to the loss of C-H...O bond between K227 and S319. 
(Note that the residue K227 is only conserved in the GATE domain of DRA family members, 
therefore its interacting partners could not be identified in the MalK structure.) 
A proposed model for the role of the conserved motifs in the C-terminal domain of DrrA: 
The biochemical data presented in this article show that the three conserved glycines present in 
the GATE domain provide structural integrity and flexibility to this region of DrrA, which is crit-
ical for maintaining stability and function of the DrrAB complex.  The analyses of the crystal 
structure of MalK and the DrrA model suggest that residue G215 forms hydrogen bonds with 
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important residues in the Walker A motif which have direct interactions with ATP.  We also 
found that both the Walker A loop and the G-loop (containing G215) move together in a compa-
rable manner on ATP binding.  Interestingly, the atomic analysis of amino acid K227, present at 
the C-terminal side of the GATE domain, showed that it has close interactions with residue S319 
present in the extreme C terminus of DrrA.  The finding that the mutation of K227 to K227R re-
sults in a four-fold increase in its distance from S319, therefore effectively preventing the for-
mation of a hydrogen bond between these residues, is noteworthy.  Previous analysis of S319 
and the adjoining conserved motifs DEF and CREEM showed that this region is involved in di-
rect interaction with the N-terminus of DrrB, therefore implying the role of K227/S319 interac-
tion in DrrA-DrrB communication.  
Putting all of the biochemical and structural analyses together, we propose that the GATE 
domain functions as a transducer of conformational changes (resulting from ATP binding) from 
DrrA to DrrB.  Specifically, G215 in the G-loop senses the conformational changes resulting 
from ATP binding to Walker A, which is seen in a comparable movement of the Walker A loop 
and the G-loop (Fig. 2.8B).  K227 in the GATE domain is then able to transduce those changes 
to DrrB through its interaction with S319.  Previous studies from this lab showed that S23 in the 
N terminus of DrrB also contacts residue Y89 in the conserved Q-loop region of DrrA.  Moreo-
ver, conformation of the N terminal region of DrrB affects the conformation of Y89C-mediated 
DrrA homodimer, which led to the proposal that the N terminus of DrrB may be important for 
transducing conformational changes resulting from doxorubicin binding in DrrB to DrrA [9].  
Together, these two sets of studies therefore suggest that the N-terminal cytoplasmic tail of DrrB 
is involved in 2-way communication between DrrA and DrrB.  The first conformational change 
resulting from doxorubicin binding to DrrB involves transmission from DrrB to the dimeric in-
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terface of DrrA, thus causing the closed state of the NBD dimer.  The second involves a signal 
resulting from ATP binding at the dimeric interface of DrrA, which promotes the transition of 
DrrB from inward-facing to an outward-facing conformation required for drug efflux.  In Fig. 
2.9, a working model is proposed to illustrate these communications.  In Conformation I (Confo. 
I) of the DrrAB complex, the transport process is initiated by binding of doxorubicin to DrrB.  
The resulted conformational changes promote the interaction between the N terminus of DrrB 
(represented by S23C) and Y89C, which in turn brings the two NBDs closer to each other and 
consequently increases the binding affinity of NBD for ATP.  This step explains how ATP bind-
ing is stimulated by doxorubicin, a previous finding in our laboratory [6].  Binding of two mole-
cules of ATP produces the fully closed state of the DrrA dimer (Confo. II).  The ATP-binding 
induces conformational changes in Walker A and the G-loop (containing G215), which is then 
transmitted to DrrB through a K227-S319-S23 cascade.  As a result, DrrB undergoes a shift from 
an inward-facing to an outward-facing conformation, and doxorubicin is translocated out of the 
cell (Confo. III).   Finally, ATP is hydrolyzed, and the complex will be restored to its resting 
state (Confo. IV).  A much more extensive analysis of the conformational changes between dif-
ferent domains of DrrA and DrrB will be carried out in the future studies to elucidate the spatial 
and temporal sequence of events involved in ATP binding/hydrolysis and the drug transport cy-
cle.   
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Table 2.1 Effect of mutations in the GATE domain on doxorubicin resistance.   E.coli N43 cells 
carrying the indicated mutation on pDx101 were streaked on M9 plates containing different con-
centrations of doxorubicin. The growth was scored after incubation of the plates for 24 h at 37°C. 
Legend: +++, very good growth; ++, good growth; +, some growth; +/-: very weak growth; -: no 
growth.  This experiment was repeated three times. Dox, doxorubicin. 
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Fig. 2.1 ClustalW amino acid sequence alignment of the Glycine Loop And Transducer Element 
(GATE) domain of DrrA with other ABC transporters.  Panel A, alignment with members of the 
DRA family.  Top, alignment with the NBD1 of homologs.  Bottom, alignment with the NBD2 
of homologs.  Panel B, alignment with diverse ABC proteins (both importers and exporters) be-
longing to different ABC families.  The identical residues are highlighted in dark gray, while 
similar residues are highlighted in light gray. The accession number and source of each protein is 
as follows: ABCA1 (AAF86276), 2 (AAK14334), 3 (NP_001080) and 8 (AAI30281) are all 
from Homo sapiens; Pgp (NP_035206) and CFTR (P26361) are both from Mus musculus; Ced-7 
(P34358) is from Caenorhabditis elegan; MalK (P68187), BtuD (EGT68374) and MsbA 
(ABJ00331) are all from Escherichia coli; ModC (2ONK_F) is from Archaeoglobus fulgidus; 
Sav1866 (Q99T13) is from Staphylococcus aureus.  NBD1, nucleotide binding domain 1; 
NBD2, nucleotide binding domain 2.  The PDB accession numbers of the crystal structures of 
the homologs in panel B are the following. MalK, 2K6G; ModC, 2ONK; BtuD, 1L7V; pgp, 
3G60; CFTR, 1R0X; MsbA, 3B5W; Sav1866, 2HYD.  
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Fig. 2.2 The tertiary structure of the GATE domain of DrrA and other ABC homologs.  Panel A, 
Structure of the GATE domain of DrrA derived from a previously established model of DrrA 
[22].  Several key residues including A206, G215, G221, and G231 are highlighted in red, yel-
low, pink and purple colors, respectively, and the equivalent residues in the structures of other 
homologs (panels B, C and D) are also labeled with the same colors.  Panels B-D, Crystal struc-
tures of the GATE domains of DrrA homologs.  Panel B, MalK; Panel C, CFTR; Panel D, 
Sav1866.  Please refer to Fig. 2.1 for the PDB accession numbers of the crystal structures of the 
homologs.  N, N-terminus; C, C-terminus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
A 
 
 
 
 
 
 
 
B 
 
 
Fig. 2.3 Effect of point mutations in GATE domain on DrrA and DrrB expression.  Membranes 
were prepared as described under ‘Material and methods’.  15 μg of membrane protein was ana-
lyzed on 12% SDS-polyacrylamide gels, followed by Western blot analysis with anti-DrrA (top 
gel) and anti-DrrB (bottom gel) antibodies.  A nonspecific band of about 28 kDa was detected in 
the anti-DrrB blot in control membranes as well as membranes containing DrrAB protein.  Den-
sitometric scanning of the bands in these blots was performed by Multi Gauge Version 2.3 (FU-
JIFILM).  Panel B, histograms showing the ratio of mutant/wild type expression using the data 
obtained by densitometric scanning designated the wild type expression level as 100%.  Top, 
DrrA; bottom, DrrB.  Error bars represent standard deviation.   
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Fig. 2.4 β-galactosidase activity of the drrA-lacZ and drrAB-lacZ translational fusions.The β-
galactosidase activity of the fusion proteins was determined in Miller units per milligrams of to-
tal cell protein, as described under ‘Material and Methods’.  Panel A, LA330 (drrA::lacZ fusion) 
and LA330-based G215A or G231A mutants; panel B, LAB15 (drrA-drrB45nt::lacZ fusion) and 
LAB15-based G215A or G231A mutants; panel C, LAB283(drrA-drrB::lacZ fusion) and 
LAB283-based G215A or G231A mutants.  Panels A-C, β-galactosidase activity of the fusion 
proteins bearing wild type DrrA or DrrAB was designated as 100%, and the activity of the corre-
sponding mutants was shown as the percentage of the wild type.  The data shown represent aver-
ages of three independent experiments.  Error bars represent standard deviation. 
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Fig. 2.5 The effect of point mutations in the GATE domain on doxorubicin efflux by the DrrAB 
transporter.  The doxorubicin efflux assay was performed, as described under ‘Material and 
Methods’.  The linear region of each efflux curve (shown in Fig. S2.1-S2.4) was used for calcu-
lation of the slope of the curve.  The slope exhibited by the host E. coli cells (containing the 
empty vector) was treated as ‘background’ and was subtracted from the calculated slopes of wild 
type and other mutants.  The efficiency of efflux in each GATE domain mutant was then calcu-
lated as the percentage of the mutant slope/wild type slope within one set.  The data shown here 
represent an average of three independent experiments.  Error bars represent standard deviation. 
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Fig. 2.6 The effect of the GATE domain mutations on ATP-binding to the DrrAB complex.  The 
UV-induced [α-32P] ATP adduct formation was analyzed in membrane fractions, as described 
under ‘Material and Methods’.  The reactions were performed either in the absence (marked by -) 
or presence (marked by +) of 35 µM doxorubicin.  The samples were analyzed by 10% SDS-
PAGE, followed by transfer to the nitrocellulose membranes.  After the membrane was exposed 
to an X-ray film and developed by autoradiography, the same membrane was probed by anti-
DrrA antibodies.  Panel A, top, autoradiograms showing [α-32P] ATP binding to wild type 
DrrAB and various GATE domain mutants.  Panel A, bottom, Western blot analysis of the nitro-
cellulose membrane from above using anti-DrrA antibodies. PanelB, a histogram showing the 
efficiency of ATP binding to the GATE domain mutants.The amount of ATP bound was normal-
ized to the amount of DrrA in each sample, as described in “Results”. The ATP-binding efficien-
cy of wild type was designated as 1.  The data presented are averages of three independent exper-
iments.  Error bars represent standard deviation. 
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Fig. 2.7 Disulfide cross-linking between cysteines introduced in the GATE domain of DrrA and 
the N-terminus of DrrB. Two different cross linkers, CuPhe and DTME were used.  Anti-DrrA 
(panel A) and anti-DrrB (panel B) antibodies were used to identify the cross-linked species.  
Panels A and B, lanes 1-2: A(Y89C).  This strain contains one cysteine in the Q-loop at residue 
89 of DrrA. The position of the previously identified DrrA homodimer is marked.  Lanes 3-5: 
A(S319C)B(S23C), which bears a cysteine residue in the C-terminus of DrrA and another cyste-
ine in the N-terminus of DrrB. A previously identified DrrAB heterodimer is marked.  Lanes 6-8: 
A(V211C)B(S23C).  This strain contains a cysteine at position 211 in the GATE domain.  Lanes 
9-11: A(T222C)B(S23C), which contains a cysteine at position 222 in the GATE domain.  In 
panel B, a species marked as B+B, which corresponds to the size of DrrB homodimer, was pro-
duced in membranes containing either S23C or the native C260.  Since this species is produced 
in all cysteine-containing DrrB variants, it is likely to be the results of nonspecific association 
between cysteines in DrrB [23].  The plus or minus at the bottom of the gels indicates the pres-
ence or absence of the cross linker. 
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Fig. 2.8 Structuralanalysis of MalK and DrrA.  Panel A, using the crystal structure of MalK, hy-
drogen bond interactions around G210 in ATP-bound (1Q12) and ATP-free (1Q1E) states of 
MalK are shown [11].  The carbon backbones of G210 in 1Q12 and 1Q1E are shown in cyan and 
slate, respectively.  Panel B, superimposition of ATP-bound (in cyan) and ATP-free (in slate) 
forms of MalK.  The NBD motifs Walker A, Walker B and ABC signature as well as the GATE 
domain are shown in both forms.  C40 residue is shown in white and G210 is shown in yellow.  
Panels C-F, using the homology model of wild type DrrA and mutants, atomic distances around 
critical GATE domain residues are shown.  Panel C, G215/A23 and G215/A45 distances in wild 
type DrrA.  Panel D, A215/A23 and A215/A45 distances in G215A mutant.  Panel E, hydrogen 
bond interaction between residues K227 and S319 in wild type DrrA.  Panel F, distance between 
R227 and S319 in K227R mutant.  In all panels except panel B, oxygen, nitrogen, and sulfur at-
om was colored in red, blue, and yellow, respectively.  The numbers near dashed lines represent 
the distances between two atoms.   
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Fig. 2.9 A model showing 2-way communication between DrrA and DrrB mediated by the N-
terminus of DrrB and different motifs in DrrA.  Both DrrA and DrrB proteins are shown as di-
mers.  DrrA protein contains two domains: an N-terminal nucleotide binding domain (shown as 
oval and filled with dark blue), and a C-terminal domain (shown as ¾ circular shape and filled 
with light blue).  Note that the GATE domain, which belongs to the C-terminal domain of DrrA, 
is shown as a separate loop in orange.  Doxorubicin and ATP are shown as yellow and red, re-
spectively.  In conformation I, doxorubicin binds to DrrB which is in its inward-facing confor-
mation.  Dox binding produces a conformational change that promotes the communication be-
tween the N-terminal tail of DrrB (represented by residue 23) and the Q-loop region of DrrA 
(represented by residue 89).  This interaction transmits the signal of doxorubicin binding to the 
NBD interface in DrrA resulting in the binding of two molecules of ATP to the binding pocket 
and the fully closed DrrA head-to-tail dimer (Confor. II).  Because of the formation of the closed 
dimer of the N-terminal domain of DrrA, the C-terminal domains are not completely visible in 
Confor. II.  In the next stage (Confor. III), ATP-binding is communicated from DrrA to DrrB.  
As described previously, ATP-binding to the NBD triggers conformational changes in the Gly-
loop of the GATE domain, which produces a cascade effect finally resulting in S319-S23 inter-
action.  These changes promote transition of DrrB from inward-facing to outward-facing con-
formation, followed by the extrusion of doxorubicin.  In the last step, ATP is hydrolyzed and the 
complex will be restored to its ATP-free conformation.  
 
 
 
 
 
 
 
 
104 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S2.1 Effect of E201D, L205V, G221A or G221S mutation on doxorubicin efflux.  E.coli 
LE392ΔuncIC cells containing the indicated plasmids were grown in TEMM medium and in-
duced with IPTG at OD=0.6, as described under Methods. Washed cells were de-energized with 
5mM DNP and loaded with 10 µM doxorubicin for 11 hours. Loaded cells were washed twice, 
and doxorubicin fluorescence was measured for 100 seconds. Doxorubicin efflux by the cell sus-
pension was then initiated by providing 20 mM glucose.  The fluorescence was monitored for 
additional 400 seconds. The linear region of each curve was used for calculation of the slope of 
the curve. The slope exhibited by the host E. coli cells (containing the empty vector) was treated 
as ‘background’ and was subtracted from the calculated slopes of wild type and other mutants. 
The slopes were: wild type DrrAB (green), 822; DrrA(E201D)DrrB (yellow), 167; 
DrrA(L205V)DrrB (pink), 326; DrrA(G221A)DrrB (blue), 51; DrrA(G221S)DrrB (cyan), 7. The 
slope of the cells containing empty vector is shown in red color.  
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Fig. S2.2 Effect of L226V or K227R mutation on doxorubicin efflux. The slopes were: wild type 
DrrAB (green), 825; DrrA(L226V)DrrB (yellow),156; DrrA(K227R)DrrB (pink), 162. The slope 
of the cells containing empty vector is shown in red color.  
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Fig. S2.3 Effect of G231A or G231S mutation on doxorubicin efflux. The slopes were: wild type 
DrrAB (green), 307; DrrA(G231A)DrrB (yellow),183; DrrA(G231S)DrrB (pink), 50. The slope 
of the cells containing empty vector is shown in red color.  
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Fig. S2.4 Effect of E201Q, G215A, G215S or G215P mutation on doxorubicin efflux. The slopes 
were: wild type DrrAB (green), 313; DrrA(G215A)DrrB (pink), 31; DrrA(G215S)DrrB (blue), 
33; The slope of G215P (cyan) or E201Q (yellow) was lower than the cells containing only vec-
tor in this experiment.    
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GENERAL DISCUSSION 
The present studies revealed the existence of two functionally important modules in the 
C-terminal domain of an ABC protein DrrA.  One of the modules present at the extreme C ter-
minus of DrrA consists of two separate motifs, DEF and CREEM, which are conserved in close 
homologs belonging to the DRA family of ABC proteins.  In the studies described  in Chapter 1 
[1], it was shown that the CREEM motif (and its immediate upstream region up to S319) inter-
acts with the N-terminus of DrrB and forms an A-B interface.  This A-B interaction is signifi-
cantly impaired by several conservative mutations, such as L303V, in the DEF motif.  Unexpect-
edly, these mutations also deplete the ATP-binding ability of DrrA.  It is previously known that 
DrrA fails to bind to ATP in the absence of DrrB due to its inability to acquire the active con-
formation by itself [2].  Therefore, it is possible that the DEF mutations result in the improperly 
assembled DrrAB complex due to the impaired A-B interaction in these mutants.  Therefore, the 
A-B interaction residing in the C-terminus of DrrA is a key factor for proper assembly of DrrAB 
complex.  This conclusion was further supported by the finding that the same set of DEF mutants 
also drastically affected co-purification of DrrA and DrrB.  Based on these biochemical data, we 
proposed that the A-B association found in this study is regulated by the behavior of the DEF 
motif, however, the detailed mechanism of this regulation remains to be further studied.  Based 
on the finding that the residues of the DEF motif as well as the upstream region up to amino acid 
S287 participates in  homodimerization of DrrA (which may be a  transient interaction), we also 
proposed that DrrA dimerization may be an important prerequisite for A-B interaction.  Addi-
tional modeling analysis confirmed that the C-terminus of DrrA forms an independent domain 
and the DEF motif is critical for conformational integrity of the C-terminal domain of DrrA, 
which may be essential for A-B interaction [1].   
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Another distinct functional module, termed GATE, was studied in Chapter 2.  This motif 
is 33 amino acids long and is present immediately after the Switch motif of the NBD in DrrA.  
Its location between the NBD in the N terminus and the conserved motifs DEF and CREEM in 
the C terminus suggests that it may play an important role in communication between these do-
mains.  Interestingly, the sequence of the GATE domain is highly conserved both among close 
homologs belonging to the DRA family as well as distantly-related ABC proteins.  The most 
striking sequence conservation is seen in the three glycines, G215, G221, and G231, present in 
the GATE domain.  Different from the DEF and the CREEM motifs (in which the mutants 
showed normal expression of DrrAB proteins), the significance of this motif was initially recog-
nized by its indispensability in maintaining the stability of DrrAB.  While mutations in either 
G215 or G221 significantly affected stability, the most drastic effect was observed in the highly 
conservative G215A mutant.  This mutant exhibited drastically reduced DrrA and completely 
depleted expression of DrrB, while the translation of both proteins by lacZ fusion analysis was 
shown to be normal.  Further structural analysis of the crystal structure of MalK [3] provided 
important insights into the understanding of the role of G215.  In MalK, residue G210 (which 
corresponds to G215) was seen to form hydrogen bonds with two other key residues within or 
near the Walker A.  Since these atomic bonds are maintained in both the ATP-bound and un-
bound forms of MalK, it suggests that G210 may be important for maintaining or constituting the 
ATP binding pocket.  Mutagenesis of G215 into Ala may disrupt these bonds and the integrity of 
the ATP binding pocket, which will produce a negative effect on the stability of DrrA as well as 
DrrB.  Different from G215, mutations of another conserved glycine in the GATE domain, 
G231, did not have a negative effect on the stability and expression level of DrrAB.  However, 
we found that while G231A exhibited relatively normal levels of ATP binding and doxorubicin 
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efflux efficiency, the G231S mutation impaired these functional features significantly.  Since the 
serine substitution is expected to make the structure of this region more rigid than glycine or ala-
nine, the drastic effect of the G231S mutation suggests that the structural flexibility conferred by 
G231 is critical for ATP-binding ability and the overall function of the DrrAB complex.  The 
importance of the glycine residue in conferring the backbone dynamics and conformational flex-
ibility has been emphasized for different categories of proteins [4-7].  Our data reveal that the 
mutations of the glycine residues in the GATE domain cause two basic types of transporter de-
fects.  One type of defect (in the case of G215A) may disrupt the structural integrity of ATP-
binding pocket and result in instability of the ABC component and therefore the whole trans-
porter.  The other type of defect (in the case of G231S) may disturb the mobility (which may be 
required for conformational changes essential for ATP catalysis or later stage) of the local re-
gion. 
Interestingly, our structural analysis also showed that another conserved residue K227 
present at the extreme C terminus of the GATE domain forms a hydrogen bond with residue 
S319 at a distance of 3.5Å.  Amino acid S319 is part of the conserved DEF/CREEM module pre-
sent in the extreme C terminus of DrrA.  Strikingly, the distance between K227 and S319 is in-
creased to 12.8 Å in a conservative mutation K227R.  The normal expression as well as ATP-
binding, but impaired drug transport function of the K227R mutant, promotes the proposal that a 
later step in the catalytic cycle (such as uncoupling of ATP binding and drug transport) must be 
disrupted in this mutant.  It is therefore possible that K227 plays a key role in transmitting con-
formational changes derived from ATP binding and/or hydrolysis to DrrB through its interaction 
with S319.  
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So far, two DrrA-DrrB interfaces have been identified by studies carried out in our labor-
atory.  These interactions include: (1) Y89 (Q-loop)-S23 (N-terminus of DrrB) [8]; and (2) S319 
(C-terminus of DrrA)-S23 [1].  It will be intriguing to understand the roles of these events in 
communication between DrrA and DrrB during the catalytic cycle and their involvement in en-
ergy transduction.  Based on the available biochemical and structural data, a catalytic model is 
proposed in Fig. 2.9 in Chapter 2.  In Conformation I, DrrB is in its inward-facing conformation.  
Doxorubicin binding to DrrB produces a conformational change in the N terminus of DrrB (rep-
resented by S23), which then promotes the interaction between S23 and the Q-loop region (rep-
resented by Y89) in DrrA [8].  In this step, the signal of doxorubicin binding is transmitted from 
DrrB to the NBD of DrrA, which increases the affinity of the NBD dimer for ATP.  Consequent-
ly, two molecules of ATP bind to the ATP-binding pocket, which in turn induces the closed form 
of the NBD dimer (Conformation II).  The next critical step involves transduction of signal of 
ATP-binding back to DrrB, which is necessary for DrrB to switch from the inward-facing to 
outward-facing conformation and the extrusion of doxorubicin.  ATP-binding induces conforma-
tional changes in Walker A and the G-loop (containing G215), which is then transmitted to DrrB 
through a K227-S319-S23 cascade.  As a result, DrrB undergoes a shift from inward-facing to 
outward-facing conformation, and doxorubicin is translocated out of the cell (Confo. III).  Final-
ly, ATP is hydrolyzed, and the complex will be restored to its resting state (Confo. IV).  In sum-
mary, our studies provide important insights into the associations between the NBD and the 
TMD of the DrrAB drug transporter and their roles in communicating conformational changes 
during the catalytic cycle.  Future studies will be directed towards in-depth understanding of the 
detailed mechanisms underlying the G215-K227-S319-S23 signaling cascade and its role in en-
ergy transduction.  
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